,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,357,2,1,,855643,5213,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
1,361,1,2,,855643,5213,Inactive,285623.0,,,,Pyruvate Kinase,Confirmatory,,
2,364,1,3,,855643,5213,Inactive,,,,,Cell Proliferation & Viability (Cytotoxicity) Assay,Confirmatory,,
3,368,2,3,,855643,5213,Inactive,4757950.0,994.0,,,Cdc25B Catalytic Domain protein tyrosine phosphatase  HTS,Screening,,
4,371,1,1,,855643,5213,Inactive,,,,,Human A549 Lung Tumor Cell Growth Inhibition Assay,Screening,,
5,373,1,4,,855643,5213,Inactive,38788193.0,1903.0,,,S1P3 Agonist Primary HTS and Confirmation Assays,Screening,,
6,374,2,3,,855643,5213,Inactive,4758204.0,1843.0,,,In vitro Primary HTS Assay for MKP-1,Screening,,
7,375,2,3,,855643,5213,Inactive,90108679.0,,,,Mycobacterium tuberculosis Pantothenate Synthetase Assay,Confirmatory,,
8,411,2,1,,855643,5213,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
9,422,1,5,,855643,5213,Inactive,21464101.0,7532.0,,,HTS for 14-3-3 protein interaction modulators,Screening,,
10,425,3,2,,855643,5213,Inactive,16758752.0,116663.0,,IC50,MKP-3 in vitro HTS assay,Confirmatory,,
11,429,1,5,,855643,5213,Inactive,4261762.0,3326.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
12,429,1,5,,855643,5213,Inactive,154146191.0,3320.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
13,430,2,4,,855643,5213,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HPDE-C7 cells),Confirmatory,,
14,431,2,4,,855643,5213,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HPDE-C7K cells),Confirmatory,,
15,432,2,4,,855643,5213,Inactive,11024684.0,12044.0,,IC50,HTS discovery of chemical inhibitors of anti-apoptotic protein Bfl-1,Confirmatory,,
16,436,2,1,,855643,5213,Inactive,68565074.0,8314.0,,,HTS for BAP1 Enzyme inhibitors,Screening,,
17,438,1,4,,855643,5213,Inactive,223468676.0,5970.0,,,Cellular assay for TNF alpha induced NFkappaB translocation,Screening,,
18,440,3,3,,855643,5213,Inactive,4503779.0,2357.0,,,Primary HTS Assay for Formylpeptide Receptor (FPR) Ligands and Primary HTS Counter-Screen Assay for Formylpeptide-Like-1 (FPRL1) Ligands,Screening,,
19,441,3,3,,855643,5213,Inactive,54112388.0,2358.0,,,Primary HTS Assay for Formylpeptide Receptor-Like-1 (FPRL1) Ligands and Primary HTS Counter-Screen Assay for Formylpeptide Receptor (FPR) Ligands,Screening,,
20,444,1,1,,855643,5213,Inactive,,,,,NFAT Signaling Pathway,Confirmatory,,
21,446,1,1,,855643,5213,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
22,449,1,5,,855643,5213,Inactive,13027636.0,1901.0,,,Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators,Screening,,
23,450,1,2,,855643,5213,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
24,453,2,2,,855643,5213,Inactive,63102437.0,1508.0,,,Cathepsin B,Screening,,
25,454,1,7,,855643,5213,Inactive,,,,,VCAM-1 Plate Reader Assay in Pooled HUVECs: Inhibition of TNFa induced VCAM-1 cell surface expression,Screening,,
26,455,1,7,,855643,5213,Inactive,,,,,VCAM-1 Plate Reader Assay in Pooled HUVECs: Augmentation of TNFa induced VCAM-1 cell surface expression,Screening,,
27,456,1,7,,855643,5213,Inactive,,,,,VCAM-1 Imaging Assay in Pooled HUVECs: Inhibition of TNFa induced VCAM-1 cell surface expression,Screening,,
28,457,1,7,,855643,5213,Inactive,,,,,VCAM-1 Imaging Assay in Pooled HUVECs: Augmentation of TNFa induced VCAM-1 cell surface expression.,Screening,,
29,460,2,2,,855643,5213,Inactive,4503155.0,1514.0,,,Cathepsin L,Screening,,
30,483,1,6,,855643,5213,Inactive,296434520.0,3064.0,,,Aggregation and Clearance of Mutant Huntingtin Protein,Screening,,
31,485,1,8,,855643,5213,Inactive,38788193.0,1903.0,,,Primary HTS Assay for S1P3 Antagonists,Screening,,
32,487,1,2,,855643,5213,Inactive,,,,,TNFalpha Induced E-Selectin Expression -  Primary screen,Screening,,
33,488,2,1,,855643,5213,Inactive,63102437.0,1508.0,,,Cathepsin B compound mixture screening,Screening,,
34,501,2,2,,855643,5213,Inactive,23110962.0,1520.0,,,Cathepsin S,Screening,,
35,518,2,6,,855643,5213,Inactive,116734717.0,249.0,,IC50,TNAP luminescent HTS assay,Confirmatory,,
36,521,2,5,,855643,5213,Inactive,18375660.0,5778.0,,IC50,"HTS Discovery of Chemical Inhibitors of HePTP, a Leukemia Target",Confirmatory,,
37,522,1,2,,855643,5213,Inactive,20070193.0,2516.0,,,Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1),Screening,,
38,524,1,3,,855643,5213,Inactive,4506055.0,5566.0,,,Primary biochemical high-throughput screening assay for inhibitors of protein kinase A (PKA) activity,Screening,,
39,525,1,3,,855643,5213,Inactive,20070193.0,2516.0,,,Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1),Screening,,
40,527,3,1,,855643,5213,Inactive,,,,,Primary HTS Assay for Inhibitors of Bacterial Quorum Sensing,Screening,,
41,528,1,4,,855643,5213,Inactive,67191027.0,3676.0,,,Allosteric Agonists for the VLA-4 Integrin,Screening,,
42,529,1,4,,855643,5213,Inactive,67191027.0,3676.0,,,Allosteric Antagonists for the VLA-4 Integrin,Screening,,
43,538,2,2,,855643,5213,Inactive,4502495.0,716.0,,,Complement factor C1s,Screening,,
44,539,1,2,,855643,5213,Inactive,116077694.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - PMK,Screening,,
45,552,1,3,,855643,5213,Inactive,,,,,Antimicrobial HTS Assay for E. coli BW25113 (wild type),Screening,,
46,555,1,2,,855643,5213,Inactive,116516899.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - MK,Screening,,
47,556,1,3,,855643,5213,Inactive,116076351.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - DPM-DC,Screening,,
48,559,2,2,,855643,5213,Inactive,147728.0,,,,RNA polymerase,Screening,,
49,560,1,2,,855643,5213,Inactive,548814.0,6095.0,,,Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA),Screening,,
50,561,1,3,,855643,5213,Inactive,548814.0,6095.0,,,Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA),Screening,,
51,565,1,4,,855643,5213,Inactive,1431733.0,,,,HIV-1 RT-RNase H  MLSCN HTS MH077605,Screening,,
52,567,1,4,,855643,5213,Inactive,55956923.0,3350.0,,,Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists,Screening,,
53,568,1,7,,855643,5213,Inactive,5729877.0,3312.0,,IC50,High Throughput Screening Assay for Hsc70 Inhibitors,Confirmatory,,
54,568,1,7,,855643,5213,Inactive,24234686.0,3312.0,,IC50,High Throughput Screening Assay for Hsc70 Inhibitors,Confirmatory,,
55,570,1,4,,855643,5213,Inactive,4505209.0,4322.0,,,Primary biochemical high-throughput screening assay for inhibitors of Matrix Metalloproteinase 13 (MMP13) activity,Screening,,
56,571,1,4,,855643,5213,Inactive,112822.0,3354.0,,,Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E),Screening,,
57,572,1,5,,855643,5213,Inactive,,,,,Human SK-BR-3 Breast Tumor Cell Growth Inhibition In a 24- Hour Assay (Pilot Screen),Screening,,
58,573,1,4,,855643,5213,Inactive,,,,,Primary Antimicrobial Assay for E. coli BW25113 &#8710;tolC::kan Protocol for 384-well HTS,Screening,,
59,574,1,3,,855643,5213,Inactive,112822.0,3354.0,,,Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E),Screening,,
60,575,1,4,,855643,5213,Inactive,,,,,Human Endothelial Cell Proliferation Assay,Screening,,
61,576,1,2,,855643,5213,Inactive,67191027.0,3676.0,,,Auto-fluorescence of compounds effecting screening of VLA-4 Integrin,Other,,
62,577,1,1,,855643,5213,Inactive,11528014.0,912267.0,,,HTS to identify Inhibitors of West Nile Virus NS2bNS3 Proteinase,Screening,,
63,580,1,5,,855643,5213,Inactive,,,,,Human H69AR Lung Tumor Cell Growth Inhibition Assay,Screening,,
64,581,2,2,,855643,5213,Inactive,15680217.0,1511.0,,,Cathepsin G,Screening,,
65,583,2,6,,855643,5213,Inactive,123271505.0,,,IC50,High Throughput Screening Assay for Hsp70 Inhibitors,Confirmatory,,
66,587,1,5,,855643,5213,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
67,588,1,4,,855643,5213,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
68,589,1,3,,855643,5213,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
69,590,1,3,,855643,5213,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
70,591,1,4,,855643,5213,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
71,592,1,6,,855643,5213,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
72,593,1,4,,855643,5213,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
73,594,1,4,,855643,5213,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
74,597,1,3,,855643,5213,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
75,598,1,4,,855643,5213,Inactive,,,,,Human H69AR Lung Tumor Cell Growth Inhibition Assay - 86K Screen,Screening,,
76,601,1,4,,855643,5213,Inactive,,,,,Identification of Molecular Probes that Reverse MRP-Mediated Drug Resistance Pilot Screen,Screening,,
77,602,1,4,,855643,5213,Inactive,,,,,Identification of Molecular Probes that Reverse MRP-Mediated Drug Resistance,Screening,,
78,604,1,3,,855643,5213,Inactive,41872583.0,9475.0,,,Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2),Screening,,
79,606,1,3,,855643,5213,Inactive,224586929.0,26191.0,,,HTS for LYP Inhibitors-an Autoimmunity Target - Primary screen,Confirmatory,,
80,606,1,3,,855643,5213,Inactive,301171662.0,26191.0,,,HTS for LYP Inhibitors-an Autoimmunity Target - Primary screen,Confirmatory,,
81,609,1,2,,855643,5213,Inactive,,,,,Chemical Complementation Assay for MKP-3,Screening,,
82,614,1,6,,855643,5213,Inactive,116734717.0,249.0,,,HTS colorimetric detection of phosphate released in TNAP reaction,Screening,,
83,615,1,6,,855643,5213,Inactive,116734717.0,249.0,,,HTS colorimetric detection of p-nitrophenol released in TNAP reaction,Screening,,
84,618,2,6,,855643,5213,Inactive,6690534.0,4323.0,,EC50,Luminescent HTS for small molecule inhibitors of MT1-MMP transcription,Confirmatory,,
85,620,2,5,,855643,5213,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HT1080 cells),Confirmatory,,
86,622,1,2,,855643,5213,Inactive,499328.0,29738.0,,,Voltage-Dependent Potassium Channel Beta Subunit (KvBeta) Negative Modulator Primary Screen,Screening,,
87,623,1,3,,855643,5213,Inactive,499328.0,29738.0,,,Voltage-Dependent Potassium Channel Beta Subunit (KvBeta) Positive Modulator: Primary Screen,Screening,,
88,624,1,2,,855643,5213,Inactive,,,,,Measurement of GPCR-mediated thallium flux through GIRK channels: Primary Screen,Screening,,
89,625,1,2,,855643,5213,Inactive,,,,,Discovery of Novel Allosteric Agonists of the M4 Muscarinic Receptor: Primary Screen,Screening,,
90,626,1,3,,855643,5213,Inactive,,,,,Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist  Primary Screen,Screening,,
91,628,2,4,,855643,5213,Inactive,113121.0,25229.0,,,Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen,Screening,,
92,629,1,3,,855643,5213,Inactive,118764400.0,2099.0,,,HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors,Screening,,
93,630,1,1,,855643,5213,Inactive,5174513.0,4088.0,,,HTS of Smad transcription factor inhibitors,Screening,,
94,631,1,4,,855643,5213,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
95,631,1,4,,855643,5213,Inactive,22538455.0,8648.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
96,633,1,3,,855643,5213,Inactive,10835013.0,2100.0,,,HTS for Estrogen Receptor-beta Coactivator Binding inhibitors,Screening,,
97,636,1,4,,855643,5213,Inactive,,,,,Modulators of Post-Golgi Transport - 384-well pilot screen,Screening,,
98,637,1,4,,855643,5213,Inactive,,,,,Modulators of Post-Golgi Transport - 1536-well pilot screen,Screening,,
99,639,1,2,,855643,5213,Inactive,118764400.0,2099.0,,,HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators,Screening,,
100,641,1,4,,855643,5213,Inactive,,,,,Allosteric Modulators of D1 Receptors: Primary Screen,Screening,,
101,645,1,4,,855643,5213,Inactive,,,,,Isolation of Inhibitors of Her-Kinase Expression - 66K library screen,Screening,,
102,648,1,3,,855643,5213,Inactive,,,,,Human Endothelial Cell Proliferation Assay in 384-well format,Screening,,
103,680,1,10,,855643,5213,Inactive,180352.0,,,,Factor XIa Mixture HTS,Screening,,
104,684,1,12,,855643,5213,Inactive,317373446.0,2161.0,,,Factor XIIa Mixture HTS,Screening,,
105,686,1,1,,855643,5213,Inactive,,,,,Zebrafish Lipid Metabolism Assay---Primary Screen,Screening,,
106,687,1,17,,855643,5213,Inactive,180352.0,,,,Factor XIa Single Well HTS,Screening,,
107,701,1,17,,855643,5213,Inactive,317373446.0,2161.0,,,Factor XIIa Single Well HTS,Screening,,
108,708,1,4,,855643,5213,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Absorbance at 340 nm,Screening,,
109,709,1,2,,855643,5213,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Autofluorescence at 339/460 nm,Screening,,
110,719,1,3,,855643,5213,Inactive,,,,,Human Lung Fibroblast Proliferation Assay,Screening,,
111,731,1,5,,855643,5213,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
112,731,1,5,,855643,5213,Inactive,32307126.0,8202.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
113,746,1,1,,855643,5213,Inactive,2507196.0,5602.0,,,Primary biochemical high-throughput screening assay for inhibitors of the c-Jun N-Terminal Kinase 3 (JNK3),Screening,,
114,750,1,3,,855643,5213,Inactive,,,,,Luminescent HTS for small molecule activators of MT1-MMP transcription,Screening,,
115,751,1,3,,855643,5213,Inactive,,,,,Disassembly of the 26S Proteasome (ATP Hydrolysis-dependent),Screening,,
116,757,1,4,,855643,5213,Inactive,8574038.0,5879.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype,Screening,,
117,758,1,4,,855643,5213,Inactive,164058.0,404007.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab7 wildtype,Screening,,
118,759,1,4,,855643,5213,Inactive,190938.0,3265.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype,Screening,,
119,760,1,4,,855643,5213,Inactive,46577642.0,404009.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab2 wildtype,Screening,,
120,761,1,4,,855643,5213,Inactive,56202836.0,,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Cdc42 wildtype,Screening,,
121,764,1,4,,855643,5213,Inactive,8574038.0,5879.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant,Screening,,
122,770,1,1,,855643,5213,Inactive,,,,,Cell Growth High Content Screening Assay of Human HT29 Colon Tumor Cells (24 Hour Treatment Protocol),Screening,,
123,771,1,2,,855643,5213,Inactive,,,,,Cell Growth High Content Screening Assay of Human HT29 Colon Tumor Cells (48 Hour Treatment Protocol),Screening,,
124,772,1,2,,855643,5213,Inactive,,,,,Cell Growth High Content Screening Assay of Human HT29 Colon Tumor Cells (72 Hour Treatment Protocol),Screening,,
125,774,1,2,,855643,5213,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Inhibition of Enzymes Frequently Used to reach a NAD/NADH Endpoint,Other,,
126,775,1,3,,855643,5213,Inactive,,,,,Screen for Chemicals that Extend Yeast Lifespan,Screening,,
127,781,1,1,,855643,5213,Inactive,27807367.0,287022.0,,,uHTS for 14-3-3/Bad interaction inhibitors,Screening,,
128,782,1,2,,855643,5213,Inactive,83627717.0,13684.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
129,782,1,2,,855643,5213,Inactive,302699239.0,1981.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
130,784,1,4,,855643,5213,Inactive,55584151.0,2629.0,,,Primary Cell Based High Throughput Screening Assay for Enhancers of Beta-Glucosidase Activity,Screening,,
131,793,1,2,,855643,5213,Inactive,4505447.0,4887.0,,,Primary cell based high-throughput screening assay for antagonists of neuropeptide Y receptor Y2 (NPY-Y2),Screening,,
132,795,1,1,,855643,5213,Inactive,,,,,MLSCN Assay for Activators of Prostate Cell Differentiation,Screening,,
133,797,1,1,,855643,5213,Inactive,115529463.0,5587.0,,,Fluorescence polarization assay for PKD inhibitors,Screening,,
134,798,2,12,,855643,5213,Inactive,180352.0,,,,Factor XIa 1536 HTS,Screening,,
135,799,1,5,,855643,5213,Inactive,134142337.0,4363.0,,,Identification of Molecular Probes that Activate MRP-1,Screening,,
136,800,2,11,,855643,5213,Inactive,317373446.0,2161.0,,,Factor XIIa 1536 HTS,Screening,,
137,803,1,4,,855643,5213,Inactive,6016094.0,8811.0,,,Primary cell-based high-throughput screening assay to identify agonists of Galanin Receptor 2 (GALR2),Screening,,
138,804,1,3,,855643,5213,Inactive,,,,,Screen for Chemicals that Shorten Yeast Lifespan,Screening,,
139,813,1,4,,855643,5213,Inactive,116734717.0,249.0,,,HTS identification of compounds activating TNAP at intermediate concentration of phosphate acceptor detected in luminescent assay,Screening,,
140,817,1,1,,855643,5213,Inactive,1360328.0,,,,Identification and characterization of compounds for addressing human bone marrow failure,Other,,
141,818,1,2,,855643,5213,Inactive,,,,,High Throughput Screen to Identify Compounds that Suppress the Growth of Human Colon Tumor Cells Lacking Oncogenic Beta Catenin Expression,Screening,,
142,827,1,2,,855643,5213,Inactive,,,,,High Throughput Screen to Identify Compounds that Suppress the Growth of Cells with a Deletion of the PTEN Tumor Suppressor,Screening,,
143,828,1,5,,855643,5213,Inactive,6016094.0,8811.0,,,Primary cell-based high-throughput screening assay to identify antagonists of Galanin Receptor 2 (GALR2),Screening,,
144,834,1,3,,855643,5213,Inactive,,,,,C. albicans biofilm killing,Screening,,
145,841,1,1,,855643,5213,Inactive,,,,,Non-Nucleoside Inhibitor of Measles Virus RNA-Dependent RNA Polymerase Complex Activity HTS Single Point (MLSMR Library),Screening,,
146,847,1,2,,855643,5213,Inactive,,,,,Human SK-BR-3 Breast Tumor Cell Growth Inhibition In a 24- Hour Assay,Screening,,
147,861,1,1,,855643,5213,Inactive,55662034.0,,,,Primary cell-based high-throughput screening assay for inhibitors of TLR4-MyD88 binding,Screening,,
148,862,1,2,,855643,5213,Inactive,13272532.0,6774.0,,,Primary cell-based high throughput screening assay to measure STAT3 inhibition,Screening,,
149,868,1,3,,855643,5213,Inactive,,,,,Screen for Chemicals that Inhibit the RAM Network,Screening,,
150,871,1,2,,855643,5213,Inactive,13272532.0,6774.0,,,Primary cell-based high throughput screening assay to measure STAT3 activation,Screening,,
151,873,1,13,,855643,5213,Inactive,6912644.0,25818.0,,,Kallikrein 5 1536 HTS,Screening,,
152,875,1,2,,855643,5213,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
153,878,1,2,,855643,5213,Inactive,,,,,NIH Compound Library Profiling: Compound and DTT Dependent Redox Cycling H2O2 Generation.,Screening,,
154,880,2,1,,855643,5213,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
155,880,2,1,,855643,5213,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
156,880,2,1,,26747209,5213,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
157,880,2,1,,26747209,5213,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
158,881,2,2,,855643,5213,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
159,884,1,2,,855643,5213,Active,13435386.0,1576.0,12.5893,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
160,885,1,2,,855643,5213,Inactive,13435386.0,1576.0,12.5893,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
161,887,1,2,,855643,5213,Inconclusive,1832253.0,246.0,39.8107,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
162,889,1,3,,855643,5213,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
163,892,1,2,,855643,5213,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
164,893,1,2,,855643,5213,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
165,893,1,2,,855643,5213,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
166,894,2,1,,855643,5213,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
167,894,2,1,,26747209,5213,Inconclusive,31542939.0,3248.0,15.8489,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
168,898,1,1,,855643,5213,Inactive,28373018.0,1239205.0,,,YopH  HTS,Screening,,
169,900,1,3,,855643,5213,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
170,902,1,2,,855643,5213,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
171,910,1,2,,855643,5213,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 654 locus,Confirmatory,,
172,914,1,3,,855643,5213,Inconclusive,32879895.0,3091.0,12.5893,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
173,915,1,3,,855643,5213,Inconclusive,32879895.0,3091.0,12.5893,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
174,920,1,2,,855643,5213,Inactive,6274552.0,6772.0,,,Primary cell-based high throughput screening assay to measure STAT1 inhibition,Screening,,
175,923,1,2,,855643,5213,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
176,924,1,2,,855643,5213,Inactive,120407068.0,7157.0,15.8489,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
177,927,1,3,,855643,5213,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
178,930,1,2,,855643,5213,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 705 locus,Confirmatory,,
179,932,1,4,,855643,5213,Inactive,6274552.0,6772.0,,,Primary cell-based high throughput screening assay to measure STAT1 activation,Screening,,
180,940,1,2,,855643,5213,Active,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
181,950,1,1,,855643,5213,Inactive,231632.0,596.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-2.",Screening,,
182,951,1,1,,855643,5213,Inactive,23396469.0,10017.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-B.",Screening,,
183,952,1,1,,855643,5213,Inactive,1572493.0,599.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-W.",Screening,,
184,995,1,2,,855643,5213,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
185,1001,2,2,,855643,5213,Inactive,116734717.0,249.0,,EC50,uHTS identification of compounds activating TNAP in the absence of phosphate acceptor performed in luminescent assay,Confirmatory,,
186,1006,1,6,,855643,5213,Inactive,,,,,Counter Screen for Luciferase-based Primary Inhibition Assays,Screening,,
187,1007,1,1,,855643,5213,Inactive,510901.0,598.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-XL.",Screening,,
188,1008,1,2,,855643,5213,Inactive,4757840.0,597.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bfl-1",Screening,,
189,1009,1,2,,855643,5213,Inactive,7582271.0,4170.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Mcl-1",Screening,,
190,1012,1,4,,855643,5213,Inactive,116734717.0,249.0,,,uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay,Screening,,
191,1016,1,4,,855643,5213,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of activators of bovine intestinal alkaline phosphatase,Screening,,
192,1018,2,5,,855643,5213,Inactive,8744934.0,,,IC50,Chemical Antagonists IAP-family anti-apoptotic proteins,Confirmatory,,
193,1019,1,4,,855643,5213,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of inhibitors of bovine intestinal alkaline phosphatase,Screening,,
194,1020,1,5,,855643,5213,Inactive,149631.0,,,,Counter Screen for Glucose-6-Phosphate Dehydrogenase-based Primary Assay,Screening,,
195,1021,1,1,,855643,5213,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Bid interaction inhibitors,Screening,,
196,1022,1,1,,855643,5213,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Noxa interaction inhibitors,Screening,,
197,1027,1,3,,855643,5213,Inactive,,,,,Counter Screen for Luciferase-based Primary Stimulation Assays,Screening,,
198,1030,2,1,,855643,5213,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
199,1030,2,1,,26747209,5213,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
200,1032,1,2,,855643,5213,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
201,1032,1,2,,855643,5213,Inactive,62201602.0,,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
202,1040,1,2,,855643,5213,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for antagonists of NPY-Y1,Screening,,
203,1046,1,6,,855643,5213,Inactive,339641.0,2147.0,,,Thrombin 1536 HTS,Screening,,
204,1048,1,1,,855643,5213,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
205,1048,1,1,,855643,5213,Inactive,32307126.0,8202.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
206,1049,1,1,,855643,5213,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
207,1049,1,1,,855643,5213,Inactive,62201602.0,,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
208,1051,1,1,,855643,5213,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
209,1051,1,1,,855643,5213,Inactive,22538455.0,8648.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
210,1063,1,1,,855643,5213,Inactive,,,,,Leishmania major promastigote HTS,Screening,,
211,1066,1,2,,855643,5213,Inactive,9937384.0,,,,High Throughput Screen to Identify Compounds that Inhibit Class II HMG-CoA Reductases  - Primary Screen,Screening,,
212,1080,1,1,,855643,5213,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin EP2 receptor - Primary Counterscreens,Other,,
213,1085,1,1,,855643,5213,Inactive,139424501.0,5176170.0,,,uHTS for Small Molecule Inhibitiors of Epstein-Barr Virus Inhibitors,Screening,,
214,1135,1,3,,855643,5213,Inactive,116734717.0,249.0,,,uHTS identification of compounds inhibiting TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
215,1136,1,3,,855643,5213,Inactive,116734717.0,249.0,,,uHTS identification of compounds activating TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
216,1203,1,3,,855643,5213,Inactive,12803275.0,3303.0,,,Primary cell-based high-throughput screening assay to identify transcriptional activators of heat shock protein 70 (Hsp70),Screening,,
217,1209,2,2,,855643,5213,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Confirmatory,,
218,1214,1,4,,855643,5213,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Screening,,
219,1216,1,5,,855643,5213,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat,Screening,,
220,1217,1,4,,855643,5213,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
221,1220,2,2,,855643,5213,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate,Confirmatory,,
222,1222,1,6,,855643,5213,Inactive,,,,EC50,High Throughput Screen for Inhibitors of ER Stress-induced Cell Death in a 384 well format.,Confirmatory,,
223,1229,1,3,,855643,5213,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Activators and Chemical Reducers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
224,1235,1,2,,855643,5213,Inactive,,,,,Alternative Pathway ELISA_orthogonal screening,Screening,,
225,1236,1,1,,855643,5213,Inactive,1628587.0,397393.0,,,uHTS for Calpain Inhibitors,Screening,,
226,1239,1,3,,855643,5213,Inactive,34577122.0,4790.0,,,High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen,Screening,,
227,1239,1,3,,855643,5213,Inactive,223468676.0,5970.0,,,High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen,Screening,,
228,1242,1,1,,855643,5213,Inactive,11094021.0,,,,C. albicans biofilm killing---Mixture HTS,Screening,,
229,1251,1,1,,855643,5213,Inactive,,,,,"Anti-Viral Drugs Against Arbovirus Infections, a Primary Screen",Screening,,
230,1273,1,1,,855643,5213,Inactive,59036749.0,3630.0,,,Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells,Screening,,
231,1274,1,2,,855643,5213,Inactive,115298672.0,653361.0,,,"uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)",Screening,,
232,1276,1,1,,855643,5213,Inactive,257380.0,351.0,,,Primary screen for compounds that activate Alzheimer's amyloid precursor,Screening,,
233,1285,1,1,,855643,5213,Inactive,257380.0,351.0,,,Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation,Screening,,
234,1296,1,1,,855643,5213,Inactive,59036749.0,3630.0,,,Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells,Screening,,
235,1304,1,2,,855643,5213,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y1,Screening,,
236,1321,1,2,,855643,5213,Inactive,47123300.0,7465.0,,,Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation,Screening,,
237,1325,1,2,,855643,5213,Inactive,62526033.0,9429.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCG2 screen, ABCB1 counter-screen",Screening,,
238,1326,1,4,,855643,5213,Inactive,42741659.0,5243.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCB1 screen, ABCG2 counter-screen",Screening,,
239,1359,1,4,,855643,5213,Inactive,4505447.0,4887.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y2,Screening,,
240,1362,1,2,,855643,5213,Inactive,,,,,Chemical Genetic Screen to Identify Inhibitors of Mitochondrial Fusion - Primary Screen,Screening,,
241,1376,1,2,,855643,5213,Inactive,15608158.0,886069.0,,IC50,Inhibitors of Mycobacterial Glucosamine-1-phosphate acetyl transferase (GlmU),Confirmatory,,
242,1377,1,1,,855643,5213,Inactive,,,,,HTS to identify inhibitors of zVAD Induced Cell Death in L929 Cells.,Screening,,
243,1379,1,2,,855643,5213,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
244,1379,1,2,,26747209,5213,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
245,1381,1,1,,855643,5213,Inactive,,,,,HCS to Identify Inhibitors of Dynein Mediated Cargo Transport on Microtubules.,Screening,,
246,1385,2,2,,855643,5213,Inactive,49168602.0,5888.0,,,Homologous recombination - Rad 51,Screening,,
247,1415,1,2,,855643,5213,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
248,1415,1,2,,855643,5213,Inactive,86301151.0,5999.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
249,1416,1,2,,855643,5213,Inactive,134304838.0,9451.0,,,Primary cell-based high-throughput screening assay to measure PERK inhibition,Screening,,
250,1421,1,1,,855643,5213,Inactive,31881630.0,5732.0,,Active Concentration,Modulators of the EP2 prostaglandin EP2 receptor - Primary Dose Response,Confirmatory,,
251,1422,1,1,,855643,5213,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
252,1423,1,2,,855643,5213,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
253,1423,1,2,,855643,5213,Inactive,74355113.0,85397.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
254,1424,1,1,,855643,5213,Inactive,34330186.0,368273.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel N1 (TRPN1),Screening,,
255,1430,1,1,,855643,5213,Inactive,70832125.0,3663016.0,,,HTS assay for inhibitors of Trypanosoma brucei hexokinase 1,Screening,,
256,1434,2,3,,855643,5213,Inactive,13124881.0,865.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
257,1434,2,3,,855643,5213,Inactive,19923198.0,861.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
258,1439,1,1,,855643,5213,Inactive,1166512.0,6000.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
259,1439,1,1,,855643,5213,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
260,1440,1,1,,855643,5213,Inconclusive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
261,1440,1,1,,855643,5213,Inconclusive,86990435.0,10287.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
262,1441,1,1,,855643,5213,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
263,1441,1,1,,855643,5213,Inactive,156416009.0,6004.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
264,1443,1,3,,855643,5213,Inactive,4507593.0,8743.0,,,uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells,Screening,,
265,1445,1,1,,855643,5213,Inactive,124512980.0,813945.0,,IC50,Inhibitors of Plasmodium falciparum M1- Family Alanyl Aminopeptidase (M1AAP),Confirmatory,,
266,1446,1,3,,855643,5213,Inactive,119579178.0,3717.0,,,Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F,Screening,,
267,1448,1,3,,855643,5213,Inactive,38174238.0,55283.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel ML3 (TRPML3),Screening,,
268,1452,1,1,,855643,5213,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
269,1454,1,1,,855643,5213,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
270,1454,1,1,,26747209,5213,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
271,1456,1,1,,855643,5213,Inactive,12003227.0,57468.0,,,Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen,Other,,
272,1457,1,1,,855643,5213,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
273,1457,1,1,,26747209,5213,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
274,1458,1,1,,855643,5213,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
275,1458,1,1,,26747209,5213,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
276,1460,1,3,,855643,5213,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
277,1460,1,3,,26747209,5213,Inconclusive,92096784.0,4137.0,22.3872,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
278,1461,1,2,,855643,5213,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
279,1463,1,1,,855643,5213,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
280,1463,1,1,,26747209,5213,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
281,1465,1,1,,855643,5213,Inactive,,,,EC50,"Screen for small molecule probes relevant to Friedreich's ataxia, Single Dose and Dose Response",Confirmatory,,
282,1466,1,2,,855643,5213,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
283,1467,1,3,,855643,5213,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
284,1467,1,3,,26747209,5213,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
285,1468,1,1,,855643,5213,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
286,1468,1,1,,26747209,5213,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
287,1469,1,1,,855643,5213,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
288,1469,1,1,,26747209,5213,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
289,1471,2,1,,26747209,5213,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
290,1476,2,1,,855643,5213,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
291,1476,2,1,,26747209,5213,Inconclusive,281307097.0,,25.1189,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
292,1477,1,1,,855643,5213,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
293,1477,1,1,,26747209,5213,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
294,1478,2,1,,855643,5213,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
295,1478,2,1,,26747209,5213,Inconclusive,281307097.0,,28.1838,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
296,1479,1,2,,855643,5213,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
297,1479,1,2,,26747209,5213,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
298,1481,1,2,,855643,5213,Inactive,111305821.0,7415.0,,,Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition,Screening,,
299,1486,1,3,,855643,5213,Inactive,,,,,Counterscreen for inhibitors of Janus kinase 2 mutant JAK2V617F: Cell-based high throughput assay to identify inhibitors of parental Ba/F3 cell viability.,Screening,,
300,1487,1,1,,855643,5213,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
301,1490,2,1,,855643,5213,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
302,1490,2,1,,26747209,5213,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
303,1496,1,4,,855643,5213,Inactive,13124881.0,865.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
304,1496,1,4,,855643,5213,Inactive,19923198.0,861.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
305,1509,1,2,,855643,5213,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
306,1510,1,3,,855643,5213,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
307,1511,1,3,,855643,5213,Inactive,487738.0,3757.0,,,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,Screening,,
308,1515,1,2,,855643,5213,Inactive,24119166.0,10741.0,,,Primary biochemical high throughput screening assay to identify inhibitors of Retinoblastoma binding protein 9 (RBBP9),Screening,,
309,1519,1,3,,26747209,5213,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
310,1527,1,3,,855643,5213,Inactive,7381449.0,14678525.0,,,Primary biochemical high throughput screening assay to identify inhibitors of VIM-2 metallo-beta-lactamase,Screening,,
311,1529,1,1,,855643,5213,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
312,1530,1,1,,855643,5213,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
313,1531,1,1,,855643,5213,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
314,1532,1,1,,855643,5213,Inactive,,,,,Rml C and D inhibition 384-well mixture HTS,Screening,,
315,1554,1,1,,855643,5213,Inactive,,,,,MLPCN Ras selective lethality-BJeLR viability,Screening,,
316,1556,1,4,,855643,5213,Inactive,27368096.0,,,,Epi-absorbance primary biochemical high throughput screening assay to identify inhibitors of IMP-1 metallo-beta-lactamase,Screening,,
317,1565,2,2,,855643,5213,Inactive,219689097.0,162466.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit PHOSPHO1,Confirmatory,,
318,1566,2,3,,855643,5213,Inactive,11545912.0,64127.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD2,Confirmatory,,
319,1578,3,2,,855643,5213,Inactive,5174617.0,10392.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD1,Confirmatory,,
320,1619,1,2,,855643,5213,Inactive,124809582.0,812021.0,,IC50,Inhibitors of Plasmodium falciparum M17- Family Leucine Aminopeptidase (M17LAP),Confirmatory,,
321,1621,1,2,,855643,5213,Inactive,,,,IC50,A Cell Based Assay for the Identification of Lead Compounds with Anti-Viral Activity Against West Nile Virus,Confirmatory,,
322,1626,1,2,,855643,5213,Inactive,,,,IC50,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
323,1631,3,1,,855643,5213,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
324,1634,3,1,,855643,5213,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
325,1654,2,2,,855643,5213,Inactive,4758208.0,1845.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit VHR1.,Confirmatory,,
326,1656,2,2,,855643,5213,Inactive,,,,,High Throughput Imaging Assay for Hepatic Lipid Droplet Formation,Screening,,
327,1662,1,2,,855643,5213,Inactive,15675770.0,901648.0,,,MLPCN Streptokinase Expression Inhibition,Screening,,
328,1663,1,2,,855643,5213,Inactive,,,,,MLPCN Platelet Activation -Dense Granule Release,Screening,,
329,1672,1,3,,855643,5213,Inactive,6680530.0,16518.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Screening,,
330,1688,1,1,,855643,5213,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
331,1700,1,2,,855643,5213,Inactive,124263658.0,688.0,,,Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5),Screening,,
332,1706,1,2,,855643,5213,Inactive,73745819.0,,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro),Screening,,
333,1721,1,2,,855643,5213,Inactive,290753097.0,,,Potency,qHTS Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
334,1722,1,2,,855643,5213,Inactive,290753097.0,,,Potency,qHTS Assay for Activators of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
335,1766,1,1,,855643,5213,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
336,1766,1,1,,855643,5213,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
337,1766,1,1,,26747209,5213,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
338,1766,1,1,,26747209,5213,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
339,1768,1,1,,855643,5213,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
340,1768,1,1,,855643,5213,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
341,1768,1,1,,26747209,5213,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
342,1768,1,1,,26747209,5213,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
343,1775,1,2,,855643,5213,Inactive,,,,,Profiling compound fluorescence on Avidin Beads with 488 nm excitation and 530 nm emission,Other,,
344,1776,1,2,,855643,5213,Inactive,,,,,Profiling compound fluorescence on GSH Beads with 488 nm excitation and 530 nm emission,Other,,
345,1777,3,2,,855643,5213,Inactive,39725940.0,4986.0,,EC50,uHTS identification of small molecule agonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
346,1778,3,3,,855643,5213,Inactive,39725940.0,4986.0,,IC50,uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
347,1779,2,2,,855643,5213,Inactive,224586929.0,26191.0,,IC50,uHTS identification of small molecule inhibitors of LYP via a fluorescence intensity assay,Confirmatory,,
348,1789,1,2,,855643,5213,Inactive,83318444.0,3320.0,,,Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90),Screening,,
349,1800,1,2,,855643,5213,Inactive,125541954.0,,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3),Screening,,
350,1813,1,2,,855643,5213,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,Screening,,
351,1814,1,2,,855643,5213,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,Screening,,
352,1817,2,2,,855643,5213,Inactive,40849930.0,5339.0,,IC50,uHTS identification of small molecule antagonists of the binding of Siah-1 and a peptide ligand via a fluorescence polarization assay.,Confirmatory,,
353,1822,1,3,,855643,5213,Inactive,23505220.0,813594.0,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP).,Screening,,
354,1825,1,1,,855643,5213,Inactive,,,,,Luminescence-based counterscreen assay for KLF5 inhibitors: cell-based high throughput screening assay to identify cytotoxic compounds using the IEC-6 intestinal epithelial cell line.,Screening,,
355,1832,2,1,,855643,5213,Inactive,55976631.0,178296.0,,,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,Screening,,
356,1845,1,2,,855643,5213,Inactive,125541954.0,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors: biochemical high-throughput screening assay to identify compounds that cause fluorescent intercalator displacement (FID),Screening,,
357,1850,2,1,,855643,5213,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
358,1861,2,1,,855643,5213,Inactive,119607128.0,2831.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7).,Screening,,
359,1863,2,1,,855643,5213,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
360,1865,1,1,,855643,5213,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
361,1865,1,1,,26747209,5213,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
362,1875,2,1,,855643,5213,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,Screening,,
363,1885,2,1,,855643,5213,Inactive,,,,,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,Screening,,
364,1899,1,3,,855643,5213,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
365,1903,2,3,,855643,5213,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
366,1906,1,3,,855643,5213,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
367,1910,1,2,,855643,5213,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,Screening,,
368,1947,1,2,,855643,5213,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
369,1948,1,1,,26747209,5213,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
370,1950,1,3,,855643,5213,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
371,1956,1,1,,855643,5213,Inactive,,,,Conc @ Max Fold Increase,A high-throughput screen to identify small molecule compounds that augment HSV replication,Confirmatory,,
372,1961,2,2,,855643,5213,Inactive,33695107.0,9290.0,,EC50,Image-based HTS for Selective Agonists of GPR55,Confirmatory,,
373,1962,1,2,,855643,5213,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
374,1974,1,2,,855643,5213,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
375,1984,1,3,,855643,5213,Inactive,118026946.0,17979.0,,IC50,Fluorescence for the identification of compounds that decrease p/CIP protein stability,Confirmatory,,
376,1986,1,2,,855643,5213,Inactive,45357394.0,,,IC50,uHTS fluorescence assay for the identification of Human Immunodeficiency Virus Fusion Inhibitors.,Confirmatory,,
377,1987,1,2,,855643,5213,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
378,2006,3,2,,855643,5213,Inactive,4507785.0,7329.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
379,2006,3,2,,855643,5213,Inactive,13111961.0,10054.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
380,2006,3,2,,855643,5213,Inactive,17390638.0,10055.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
381,2012,3,2,,855643,5213,Inactive,45219878.0,7458.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (eIF4H),Confirmatory,,
382,2013,2,2,,855643,5213,Inactive,33695107.0,9290.0,,IC50,Image-Based HTS for Selective Antagonists for GPR55,Confirmatory,,
383,2014,3,2,,855643,5213,Inactive,46367787.0,26986.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP),Confirmatory,,
384,2016,1,3,,855643,5213,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
385,2023,1,3,,855643,5213,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
386,2025,1,3,,855643,5213,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
387,2029,1,3,,855643,5213,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
388,2052,2,1,,855643,5213,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
389,2057,1,2,,855643,5213,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
390,2058,3,2,,855643,5213,Inactive,33695097.0,2859.0,,IC50,Image-Based HTS for Selective Antagonists of GPR35,Confirmatory,,
391,2066,1,4,,855643,5213,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
392,2071,2,2,,855643,5213,Inactive,14719829.0,22861.0,,,Colorimetric  Assay for Inhibitors for NALP1,Screening,,
393,2073,2,3,,855643,5213,Inactive,2625023.0,83589.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
394,2073,2,3,,855643,5213,Inactive,4502523.0,774.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
395,2094,1,2,,855643,5213,Inactive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
396,2094,1,2,,855643,5213,Inactive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
397,2094,1,2,,855643,5213,Inactive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
398,2097,1,2,,855643,5213,Inactive,21361340.0,2932.0,,,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,Screening,,
399,2098,1,1,,855643,5213,Inactive,62740231.0,15499.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,Screening,,
400,2099,1,1,,855643,5213,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
401,2100,1,1,,855643,5213,Inconclusive,119393891.0,2548.0,35.4813,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen,Confirmatory,,
402,2101,1,1,,855643,5213,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
403,2101,1,1,,26747209,5213,Inconclusive,496369.0,2629.0,28.1838,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
404,2107,1,1,,855643,5213,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
405,2107,1,1,,26747209,5213,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
406,2112,1,1,,855643,5213,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
407,2112,1,1,,26747209,5213,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
408,2129,1,2,,855643,5213,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
409,2130,1,3,,855643,5213,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
410,2147,1,1,,855643,5213,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
411,2147,1,1,,26747209,5213,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
412,2156,2,2,,855643,5213,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Screening,,
413,2174,1,3,,855643,5213,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
414,2177,1,3,,855643,5213,Active,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
415,2205,1,1,,855643,5213,Inactive,29788785.0,203068.0,,,HCS assay for microtubule stabilizers,Screening,,
416,2216,1,3,,855643,5213,Inactive,,,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,Screening,,
417,2221,1,2,,855643,5213,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
418,2227,1,2,,855643,5213,Inactive,2935630.0,22066.0,,,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),Screening,,
419,2232,1,2,,855643,5213,Active,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based biochemical high throughput confirmation assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
420,2234,1,2,,855643,5213,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
421,2235,1,2,,855643,5213,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
422,2237,1,2,,855643,5213,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,Screening,,
423,2239,1,2,,855643,5213,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,Screening,,
424,2242,1,1,,855643,5213,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
425,2247,1,2,,855643,5213,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,Screening,,
426,2280,2,3,,855643,5213,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
427,2288,1,1,,855643,5213,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/orActivators of miR-21,Confirmatory,,
428,2289,1,1,,855643,5213,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/or Inhibitors of miR-21,Confirmatory,,
429,2300,1,3,,855643,5213,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
430,2314,1,2,,855643,5213,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
431,2314,1,2,,855643,5213,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
432,2315,1,2,,855643,5213,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
433,2315,1,2,,855643,5213,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
434,2326,1,1,,855643,5213,Inactive,194352380.0,,,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
435,2380,1,2,,855643,5213,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
436,2391,1,1,,855643,5213,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
437,2417,1,1,,855643,5213,Inactive,4506243.0,5725.0,,,High Content Assay for Compounds that inhibit the Assembly of the Perinucleolar Compartment,Screening,,
438,2435,1,2,,855643,5213,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
439,2445,1,2,,855643,5213,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
440,2451,1,2,,855643,5213,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
441,2451,1,2,,26747209,5213,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
442,2462,1,1,,855643,5213,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
443,2462,1,1,,855643,5213,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
444,2472,1,2,,855643,5213,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
445,2472,1,2,,26747209,5213,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
446,2517,2,1,,855643,5213,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
447,2517,2,1,,26747209,5213,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
448,2520,1,4,,855643,5213,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
449,2521,1,3,,855643,5213,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
450,2524,1,2,,855643,5213,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
451,2528,1,2,,855643,5213,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
452,2528,1,2,,26747209,5213,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
453,2540,1,2,,855643,5213,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
454,2544,1,2,,855643,5213,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
455,2546,1,1,,855643,5213,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
456,2546,1,1,,26747209,5213,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
457,2549,1,1,,855643,5213,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
458,2549,1,1,,26747209,5213,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
459,2550,1,3,,855643,5213,Inactive,160333370.0,22068.0,,,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),Screening,,
460,2551,1,1,,855643,5213,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
461,2551,1,1,,26747209,5213,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
462,2553,1,2,,855643,5213,Inactive,160333370.0,22068.0,,,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),Screening,,
463,2557,1,3,,855643,5213,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
464,2563,1,1,,855643,5213,Inactive,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
465,2599,1,2,,855643,5213,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
466,2606,1,2,,855643,5213,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
467,2629,1,1,,855643,5213,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
468,2642,1,2,,855643,5213,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,Screening,,
469,2648,1,2,,855643,5213,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,Screening,,
470,2650,2,1,,855643,5213,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
471,2661,1,1,,855643,5213,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
472,2662,2,1,,855643,5213,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
473,2675,1,1,,855643,5213,Inactive,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
474,2676,1,2,,855643,5213,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
475,2685,1,1,,855643,5213,Inconclusive,,,4.1095,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
476,2690,1,2,,855643,5213,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
477,2716,1,1,,855643,5213,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
478,2717,1,2,,855643,5213,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
479,2718,1,1,,855643,5213,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
480,2732,1,1,,855643,5213,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
481,2751,2,2,,855643,5213,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
482,2796,1,4,,855643,5213,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
483,2797,1,2,,855643,5213,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
484,2805,2,2,,855643,5213,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
485,2806,2,2,,855643,5213,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
486,2825,1,2,,855643,5213,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
487,32853,3,7,,131275778,5213,Unspecified,,,,,Hepatoprotective activity against alkaline phosphatase (ALP) for thioacetamide-induced toxicity in rats at 6 mg/kg dose for 7 days by ip administration,Other,,
488,70158,5,2,,131275778,5213,Inconclusive,,,,,Minimum inhibitory concentration against Escherichia coli (CECT405); No data,Other,10987443.0,
489,74667,3,6,,131275778,5213,Unspecified,,,,,Hepatoprotective activity against glutamate oxaloacetate transaminase (GOT) for thioacetamide-induced toxicity in rats at 6 mg/kg dose for 7 days by ip administration,Other,,
490,74668,3,7,,131275778,5213,Unspecified,,,,,Hepatoprotective activity against glutamate pyruvate transaminase (GTP) for thioacetamide-induced toxicity in rats at 6 mg/kg dose for 7 days by ip administration,Other,,
491,140148,3,3,,131275778,5213,Unspecified,,,,,Inhibitory activity derived from Anastatica hierochuntica on D-Gal-induced cytotoxicity in primary cultured mouse hepatocytes at a concentration of 0 uM,Other,12643908.0,
492,140149,3,3,,131275778,5213,Unspecified,,,,,Inhibitory activity derived from Anastatica hierochuntica on D-Gal-induced cytotoxicity in primary cultured mouse hepatocytes at a concentration of 10 uM,Other,12643908.0,
493,140150,3,3,,131275778,5213,Unspecified,,,,,Inhibitory activity derived from Anastatica hierochuntica on D-Gal-induced cytotoxicity in primary cultured mouse hepatocytes at a concentration of 3 uM,Other,12643908.0,
494,140151,3,3,,131275778,5213,Unspecified,,,,,Inhibitory activity derived from Anastatica hierochuntica on D-Gal-induced cytotoxicity in primary cultured mouse hepatocytes at a concentration of 30 uM,Other,12643908.0,
495,150738,9,2,,131275778,5213,Active,,,6.8,Kd,Compound was tested for the binding affinity towards recombinant NBD2 C-terminal cytotoxic nucleotide-binding domain of mouse P-Glycoprotein,Confirmatory,10673101.0,
496,162895,7,2,,131275778,5213,Unspecified,,,,,Minimum inhibitory concentration against Proteus mirabilis (CECT170),Other,10987443.0,
497,163449,7,2,,131275778,5213,Unspecified,,,,,Minimum inhibitory concentration against Pseudomonas aeruginosa (CECT108),Other,10987443.0,
498,169920,5,1,,131275778,5213,Unspecified,,,,,"Hepatoprotective activity against thioacetamide (200 mg/kg, sc) induced toxicity in rat at 6 mg/kg dose (po x 7 days), expressed as %protection afforded in various levels of alkaline phosphatase (ALP)",Other,,
499,172516,2,5,,131275778,5213,Unspecified,,,,,"Hepatoprotective activity against thioacetamide (200 mg/kg, sc) induced toxicity in rat at 6 mg/kg dose (po x 7 days), expressed as %protection afforded in various levels of bilirubin",Other,,
500,179539,5,1,,131275778,5213,Unspecified,,,,,"Hepatoprotective activity against thioacetamide(200 mg/kg, sc) induced toxicity in rat at 6 mg/kg dose(po x 7 days), expressed as %protection afforded in various levels of glutamate oxaloacetate transaminase (GOT)",Other,,
501,179540,5,1,,131275778,5213,Unspecified,,,,,"Hepatoprotective activity against thioacetamide(200 mg/kg, sc) induced toxicity in rat at 6 mg/kg dose(po x 7 days), expressed as %protection afforded in various levels of glutamate pyruvate transaminase (GPT)",Other,,
502,180201,6,1,,131275778,5213,Unspecified,,,,,Hepatoprotective activity against thioacetamide-induced toxicity in various levels of serum ALP in rats was evaluated at 10 mg/kg dose (p.o. x 7 days),Other,9871600.0,
503,180202,6,1,,131275778,5213,Unspecified,,,,,Hepatoprotective activity against thioacetamide-induced toxicity in various levels of serum GOT in rats was evaluated at 10 mg/kg dose (p.o. x 7 days),Other,9871600.0,
504,180203,6,1,,131275778,5213,Unspecified,,,,,Hepatoprotective activity against thioacetamide-induced toxicity in various levels of serum GPT in rats was evaluated at 10 mg/kg dose (p.o. x 7 days),Other,9871600.0,
505,187634,3,3,,131275778,5213,Unspecified,,,,,Tested for release of glutamic pyruvic transaminase (GPT) from CCl4 induced toxicity in primary cultures of rat hepatocytes at 1 uM concentration,Other,12467621.0,
506,187635,3,3,,131275778,5213,Unspecified,,,,,Tested for release of glutamic pyruvic transaminase (GPT) from CCl4 induced toxicity in primary cultures of rat hepatocytes at 10 uM concentration,Other,12467621.0,
507,187636,3,3,,131275778,5213,Unspecified,,,,,Tested for release of glutamic pyruvic transaminase (GPT) from CCl4 induced toxicity in primary cultures of rat hepatocytes at 50 uM concentration,Other,12467621.0,
508,188495,2,4,,131275778,5213,Unspecified,,,,,"% protection measured by glutamate oxaloacetate transaminase level, against thioacetamide-induced hepatic damage in rats, at 6 mg/Kg peroral dose",Other,,
509,188496,2,4,,131275778,5213,Unspecified,,,,,"% protection of glutamate pyruvate transaminase level, against thioacetamide-induced hepatic damage in rats, at 6 mg/Kg peroral dose",Other,,
510,188678,2,4,,131275778,5213,Unspecified,,,,,Hepatoprotective activity against thioacetamide-induced toxicity in rats at a dose of 6 mg/Kg dose (p.o. x 7 days) expressed as % protection afforded in alkyl phosphatase (ALP) levels,Other,,
511,188680,2,4,,131275778,5213,Unspecified,,,,,"Hepatoprotective activity against thioacetamide-induced toxicity in rats at a dose of 6 mg/Kg dose (p.o. x 7 days), expressed as % protection afforded in glutamate oxaloacetate transaminase (GOT) levels",Other,,
512,188681,2,4,,131275778,5213,Unspecified,,,,,"Hepatoprotective activity against thioacetamide-induced toxicity in rats at a dose of 6 mg/Kg dose (p.o. x 7 days), expressed as % protection afforded in glutamate pyruvate transaminase (GPT) levels",Other,,
513,188682,2,4,,131275778,5213,Unspecified,,,,,"Hepatoprotective activity against thioacetamide-induced toxicity in rats at a dose of 6 mg/Kg dose (p.o. x 7 days), expressed as % protection afforded in serum bilirubin levels",Other,,
514,188834,3,3,,131275778,5213,Unspecified,,,,,Percent protection afforded by the compound in serum alkaline phosphatase (APL) level was determined,Other,9871600.0,
515,188835,3,3,,131275778,5213,Unspecified,,,,,Percent protection afforded by the compound in serum glutamate oxaloacetate transaminase (GOT) level was determined,Other,9871600.0,
516,188836,3,3,,131275778,5213,Unspecified,,,,,Percent protection afforded by the compound in serum glutamate pyruvate transaminase (GPT) level was determined,Other,9871600.0,
517,188847,2,4,,131275778,5213,Unspecified,,,,,Percent protection against thioacetamide-induced toxicity in rats using acid phosphatase(ACP) at peroral dose of 6 mg/kg for 7 days of compound,Other,,
518,188848,2,4,,131275778,5213,Unspecified,,,,,Percent protection against thioacetamide-induced toxicity in rats using acid phosphatase(ACP),Other,,
519,188849,2,4,,131275778,5213,Unspecified,,,,,Percent protection against thioacetamide-induced toxicity in rats using alkaline phosphatase (ALP) when peroral administration of compound 6 mg/kg for 7 days,Other,,
520,188850,2,4,,131275778,5213,Unspecified,,,,,Percent protection against thioacetamide-induced toxicity in rats using glutamate dehydrogenase (GIDH) when peroral administration of compound 6 mg/kg for 7 days,Other,,
521,188851,2,4,,131275778,5213,Unspecified,,,,,Percent protection against thioacetamide-induced toxicity in rats using glutamate oxaloacetate transaminase (GOT) when peroral administration of compound 6 mg/kg for 7 days,Other,,
522,188852,2,4,,131275778,5213,Unspecified,,,,,Percent protection against thioacetamide-induced toxicity in rats using glutamate pyruvate transaminase (GPT) when peroral administration of compound 6 mg/kg for 7 days,Other,,
523,188854,2,4,,131275778,5213,Unspecified,,,,,Percent protection in alcohol-induced model using acid phosphatase(ACP) at peroral dose of 6 mg/kg for 7 days,Other,,
524,188855,2,4,,131275778,5213,Unspecified,,,,,Percent protection in alcohol-induced model using acid phosphatase(ACP) when peroral administration of compound 12 mg/kg for 7 days,Other,,
525,188856,2,4,,131275778,5213,Unspecified,,,,,Percent protection in alcohol-induced model using alkaline phosphatase(ALP) when peroral administration of compound 12 mg/kg for 7 days,Other,,
526,188857,2,4,,131275778,5213,Unspecified,,,,,Percent protection in alcohol-induced model using alkaline phosphatase(ALP) when peroral administration of compound 6 mg/kg for 7 days,Other,,
527,188858,2,4,,131275778,5213,Unspecified,,,,,Percent protection in alcohol-induced model using glutamate dehydrogenase(GIDH) when peroral administration of compound 12 mg/kg for 7 days,Other,,
528,188859,2,4,,131275778,5213,Unspecified,,,,,Percent protection in alcohol-induced model using glutamate dehydrogenase(GIDH) when peroral administration of compound 6 mg/kg for 7 days,Other,,
529,188860,2,4,,131275778,5213,Unspecified,,,,,Percent protection in alcohol-induced model using glutamate oxaloacetate transaminase(GOT) when peroral administration of compound 12 mg/kg for 7 days,Other,,
530,188861,2,4,,131275778,5213,Unspecified,,,,,Percent protection in alcohol-induced model using glutamate oxaloacetate transaminase(GOT) when peroral administration of compound 6 mg/kg for 7 days,Other,,
531,188862,2,4,,131275778,5213,Unspecified,,,,,Percent protection in alcohol-induced model using glutamate pyruvate transaminase(GPT) at peroral dose of 12 mg/kg for 7 days,Other,,
532,188863,2,4,,131275778,5213,Unspecified,,,,,Percent protection in alcohol-induced model using glutamate pyruvate transaminase(GPT) when peroral administration of compound 6 mg/kg for 7 days,Other,,
533,188864,2,4,,131275778,5213,Unspecified,,,,,Percent protection in carbon tetrachloride-induced model using acid phosphatase(ACP) when peroral administration of compound 6 mg/kg for 7 days,Other,,
534,188987,2,4,,131275778,5213,Unspecified,,,,,Percent protection in carbon tetrachloride-induced model using alkaline phosphatase(ALP) when peroral administration of compound 6 mg/kg for 7 days,Other,,
535,188988,2,4,,131275778,5213,Unspecified,,,,,Percent protection in carbon tetrachloride-induced model using glutamate dehydrogenase(GIDH) when peroral administration of compound 6 mg/kg for 7 days,Other,,
536,188989,2,4,,131275778,5213,Unspecified,,,,,Percent protection in carbon tetrachloride-induced model using glutamate oxaloacetate transaminase(GOT) when peroral administration of compound 6 mg/kg for 7 days,Other,,
537,188990,2,4,,131275778,5213,Unspecified,,,,,Percent protection in carbon tetrachloride-induced model using glutamate pyruvate transaminase(GPT) when peroral administration of compound 6 mg/kg for 7 days,Other,,
538,188992,2,4,,131275778,5213,Unspecified,,,,,Percent protection in galactosamine-induced model using alkaline phosphatase(ALP) when peroral administration of compound 6 mg/kg for 7 days,Other,,
539,188993,2,4,,131275778,5213,Unspecified,,,,,Percent protection in galactosamine-induced model using glutamate dehydrogenase(GIDH) when peroral administration of compound 6 mg/kg for 7 days,Other,,
540,188994,2,4,,131275778,5213,Unspecified,,,,,Percent protection in galactosamine-induced model using glutamate oxaloacetate transaminase(GOT) when peroral administration of compound 6 mg/kg for 7 days,Other,,
541,188995,2,4,,131275778,5213,Unspecified,,,,,Percent protection in galactosamine-induced model using glutamate pyruvate transaminase(GPT) when peroral administration of compound 6 mg/kg for 7 days,Other,,
542,188996,2,4,,131275778,5213,Unspecified,,,,,Percent protection in paracetamol-induced model using acid phosphatase(ACP) when peroral administration of compound 6 mg/kg for 7 days,Other,,
543,188997,2,4,,131275778,5213,Unspecified,,,,,Percent protection in paracetamol-induced model using alkaline phosphatase(ALP) at peroral dose of 6 mg/kg for 7 days,Other,,
544,188998,2,4,,131275778,5213,Unspecified,,,,,Percent protection in paracetamol-induced model using glutamate dehydrogenase(GIDH) when peroral administration of compound 6 mg/kg for 7 days,Other,,
545,188999,2,4,,131275778,5213,Unspecified,,,,,Percent protection in paracetamol-induced model using glutamate oxaloacetate transaminase(GOT) when peroral administration of compound 6 mg/kg for 7 days,Other,,
546,189000,2,4,,131275778,5213,Unspecified,,,,,Percent protection in paracetamol-induced model using glutamate pyruvate transaminase(GPT) when peroral administration of compound 6 mg/kg for 7 days,Other,,
547,189023,2,4,,131275778,5213,Unspecified,,,,,"Tested for hepatoprotective activity against thioacetamide-induced hepatic damage in rat at 6 mg/kg, expressed as % protection afforded in ACP levels",Other,,
548,189148,2,4,,131275778,5213,Unspecified,,,,,"Tested for hepatoprotective activity against thioacetamide-induced hepatic damage in rat at 6 mg/kg, expressed as % protection afforded in ALP levels",Other,,
549,189149,2,4,,131275778,5213,Unspecified,,,,,"Tested for hepatoprotective activity against thioacetamide-induced hepatic damage in rat at 6 mg/kg, expressed as % protection afforded in GIDH levels",Other,,
550,195379,2,4,,131275778,5213,Unspecified,,,,,Hepatoprotective activity against bilirubin for thioacetamide-induced toxicity in rats at 6 mg/kg dose for 7 days by ip administration,Other,,
551,201240,6,2,,131275778,5213,Unspecified,,,,,"Minimum inhibitory concentration, that inhibits growth of Staphylococcus aureus in the presence of subinhibitory (30 ug/mL) Berberine",Other,11170636.0,
552,206791,7,2,,131275778,5213,Unspecified,,,,,Minimum Inhibitory concentration against Staphylococcus aureus (CECT240),Other,10987443.0,
553,233143,3,3,,131275778,5213,Unspecified,,,,,Change in Fmax was determined,Other,10673101.0,
554,270110,8,1,,131275778,5213,Unspecified,,,,,"Alanine aminotransferase activity in Sprague-Dawley rat serum at 25 mg/kg, po",Other,16797983.0,
555,270111,8,1,,131275778,5213,Unspecified,,,,,"Aspartate aminotransferase activity in Sprague-Dawley rat serum at 25 mg/kg, po",Other,16797983.0,
556,270112,8,1,,131275778,5213,Unspecified,,,,,"Gamma-glutamyl transferase activity in Sprague-Dawley rat serum at 25 mg/kg, po",Other,16797983.0,
557,270113,8,1,,131275778,5213,Unspecified,,,,,"Glucose level in Sprague-Dawley rat serum at 25 mg/kg, po",Other,16797983.0,
558,270114,8,1,,131275778,5213,Unspecified,,,,,"Total bilirubin level in Sprague-Dawley rat serum at 25 mg/kg, po",Other,16797983.0,
559,270115,8,1,,131275778,5213,Unspecified,,,,,"Triglyceride level in Sprague-Dawley rat serum at 25 mg/kg, po",Other,16797983.0,
560,270116,8,1,,131275778,5213,Unspecified,,,,,"Cholesterol level in Sprague-Dawley rat serum at 25 mg/kg, po",Other,16797983.0,
561,270117,8,1,,131275778,5213,Unspecified,,,,,"Total protein level in Sprague-Dawley rat serum at 25 mg/kg, po",Other,16797983.0,
562,270118,8,1,,131275778,5213,Unspecified,,,,,"Albumin level in Sprague-Dawley rat serum at 25 mg/kg, po",Other,16797983.0,
563,354702,3,6,,131275778,5213,Unspecified,,,,,Antihepatotoxic activity against CCl4-induced toxicity in rat hepatocytes assessed as effect on GPT activity at 5 uM by Reitman-Fankel method relative to control,Other,8882436.0,
564,354703,3,6,,131275778,5213,Unspecified,,,,,Antihepatotoxic activity against CCl4-induced toxicity in rat hepatocytes assessed as effect on SDH activity at 5 uM by Geralch method relative to control,Other,8882436.0,
565,359150,3,5,,131275778,5213,Unspecified,,,,,Hepatoprotective activity against D-galactosamine/TNFalpha-induced cell death in primary cultured mouse hepatocytes assessed as cell viability at 100 uM treated for 30 mins before TNFalpha challenge measured after 18 hrs by MTT assay relative to normal hepatocytes,Other,11277757.0,
566,359151,3,5,,131275778,5213,Unspecified,,,,,Hepatoprotective activity against D-galactosamine/TNFalpha-induced cell death in primary cultured mouse hepatocytes assessed as cell viability at 50 uM treated for 30 mins before TNFalpha challenge measured after 18 hrs by MTT assay relative to normal hepatocytes,Other,11277757.0,
567,359152,3,5,,131275778,5213,Unspecified,,,,,Hepatoprotective activity against D-galactosamine/TNFalpha-induced cell death in primary cultured mouse hepatocytes assessed as cell viability at 25 uM treated for 30 mins before TNFalpha challenge measured after 18 hrs by MTT assay relative to normal hepatocytes,Other,11277757.0,
568,359153,3,5,,131275778,5213,Unspecified,,,,,Hepatoprotective activity against D-galactosamine/TNFalpha-induced cell death in primary cultured mouse hepatocytes at 100 uM treated for 30 mins before TNFalpha challenge measured after 18 hrs by MTT assay relative to control,Other,11277757.0,
569,359154,3,5,,131275778,5213,Unspecified,,,,,Hepatoprotective activity against D-galactosamine/TNFalpha-induced cell death in primary cultured mouse hepatocytes at 50 uM treated for 30 mins before TNFalpha challenge measured after 18 hrs by MTT assay relative to control,Other,11277757.0,
570,359155,3,5,,131275778,5213,Unspecified,,,,,Hepatoprotective activity against D-galactosamine/TNFalpha-induced cell death in primary cultured mouse hepatocytes at 25 uM treated for 30 mins before TNFalpha challenge measured after 18 hrs by MTT assay relative to control,Other,11277757.0,
571,359156,6,4,,131275778,5213,Active,,,29.9,IC50,Hepatoprotective activity against D-galactosamine/TNFalpha-induced cell death in primary cultured mouse hepatocytes treated for 30 mins before TNFalpha challenge measured after 18 hrs by MTT assay,Confirmatory,11277757.0,
572,359485,3,5,,131275778,5213,Unspecified,,,,,Hepatoprotective activity in mouse hepatocytes assessed protection against D-galactosamine/TNFalpha-induced cell death at 12.5 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs,Other,11325227.0,
573,359486,3,5,,131275778,5213,Unspecified,,,,,Hepatoprotective activity in mouse hepatocytes assessed protection against D-galactosamine/TNFalpha-induced cell death at 25 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs,Other,11325227.0,
574,359487,3,5,,131275778,5213,Unspecified,,,,,Hepatoprotective activity in mouse hepatocytes assessed protection against D-galactosamine/TNFalpha-induced cell death at 50 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs,Other,11325227.0,
575,359488,6,4,,131275778,5213,Unspecified,,,82.4,IC50,Hepatoprotective activity in mouse hepatocytes assessed inhibition of D-galactosamine/TNFalpha-induced cell death dosed administered before 30 mins of TNFalpha challenge measured after 18 hrs,Confirmatory,11325227.0,
576,359491,3,5,,131275778,5213,Unspecified,,,,,Hepatoprotective activity in mouse hepatocytes assessed inhibition of D-galactosamine/TNFalpha-induced cell death at 12.5 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs,Other,11325227.0,
577,359492,3,5,,131275778,5213,Unspecified,,,,,Hepatoprotective activity in mouse hepatocytes assessed inhibition of D-galactosamine/TNFalpha-induced cell death at 25 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs,Other,11325227.0,
578,359493,3,5,,131275778,5213,Unspecified,,,,,Hepatoprotective activity in mouse hepatocytes assessed inhibition of D-galactosamine/TNFalpha-induced cell death at 50 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs,Other,11325227.0,
579,359496,3,5,,131275778,5213,Unspecified,,,,,Hepatoprotective activity against D-galactosamine/TNFalpha-induced cell death in mouse hepatocytes assessed cell survival rate at 12.5 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs by MTT assay,Other,11325227.0,
580,359497,3,5,,131275778,5213,Unspecified,,,,,Hepatoprotective activity against D-galactosamine/TNFalpha-induced cell death in mouse hepatocytes assessed cell survival rate at 25 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs by MTT assay,Other,11325227.0,
581,359682,3,5,,131275778,5213,Unspecified,,,,,Hepatoprotective activity against D-galactosamine/TNFalpha-induced cell death in mouse hepatocytes assessed cell survival rate at 50 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs by MTT assay,Other,11325227.0,
582,360503,12,1,,131275778,5213,Unspecified,,,,,Antioxidant activity assessed as DPPH radical scavenging activity,Other,8594153.0,
583,360506,7,1,,131275778,5213,Unspecified,,,,,"Antihepatotoxic activity against carbon tetrachloride-induced hepatotoxicity in Wistar rat liver assessed as decrease in serum glutamate pyruvate transaminase level at 35 mg/kg, ip administered 24 hrs before carbon tetrachloride intoxication",Other,8594153.0,
584,360507,3,5,,131275778,5213,Unspecified,,,,,"Antihepatotoxic activity against carbon tetrachloride-induced hepatotoxicity in Wistar rat liver assessed as decrease in serum glutamate pyruvate transaminase level at 35 mg/kg, ip administered 24 hrs before carbon tetrachloride intoxication relative to control",Other,8594153.0,
585,360510,4,4,,131275778,5213,Unspecified,,,,,"Antihepatotoxic activity against carbon tetrachloride-induced hepatotoxicity in Wistar rat liver assessed as decrease in hepatic malondialdehyde level at 35 mg/kg, ip administered 24 hrs before carbon tetrachloride intoxication",Other,8594153.0,
586,360511,3,4,,131275778,5213,Unspecified,,,,,"Antihepatotoxic activity against carbon tetrachloride-induced hepatotoxicity in Wistar rat liver assessed as decrease in hepatic malondialdehyde level at 35 mg/kg, ip administered 24 hrs before carbon tetrachloride intoxication relative to control",Other,8594153.0,
587,376573,4,2,,131275778,5213,Unspecified,,,,,Hepatoprotective activity in Wistar rat CCL4-damaged hepatocyte assessed as blockade of glutamic pyruvic transaminase release at 100 uM relative to control,Other,10924192.0,
588,377041,3,6,,131275778,5213,Active,,,,,Hepatoprotective activity against H2O2-induced hepatotoxicity in Wistar rat hepatocytes assessed as reduction in glutamic pyruvate transaminase release at 100 uM after 1 hr relative to control,Other,15679328.0,
589,379988,3,5,,131275778,5213,Unspecified,,,,,Hepatoprotective activity against mouse hepatocytes assessed as inhibition of D-galactosamine/TNFalpha-induced cell death at 25 uM after 18 hrs by MTT assay,Other,10785422.0,
590,379989,3,5,,131275778,5213,Unspecified,,,,,Hepatoprotective activity against mouse hepatocytes assessed as inhibition of D-galactosamine/TNFalpha-induced cell death at 50 uM after 18 hrs by MTT assay,Other,10785422.0,
591,379990,3,5,,131275778,5213,Unspecified,,,,,Hepatoprotective activity against mouse hepatocytes assessed as inhibition of D-galactosamine/TNFalpha-induced cell death at 100 uM after 18 hrs by MTT assay,Other,10785422.0,
592,379991,3,5,,131275778,5213,Unspecified,,,,,Hepatoprotective activity against mouse hepatocytes assessed as inhibition of D-galactosamine/TNFalpha-induced cell death at 200 uM after 18 hrs by MTT assay,Other,10785422.0,
593,400607,4,3,,131275778,5213,Unspecified,,,,,Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression at 10 uM after 18 hrs measured as microunits of tissue factor/10'5 cells,Other,8882428.0,
594,400926,3,5,,131275778,5213,Unspecified,,,,,Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity at 3 uM after 44 hrs by MTT assay relative to control,Other,15104485.0,
595,400927,3,5,,131275778,5213,Unspecified,,,,,Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity at 10 uM after 44 hrs by MTT assay relative to control,Other,15104485.0,
596,400928,3,5,,131275778,5213,Unspecified,,,,,Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity at 30 uM after 44 hrs by MTT assay relative to control,Other,15104485.0,
597,400929,3,5,,131275778,5213,Unspecified,,,,,Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity at 100 uM after 44 hrs by MTT assay relative to control,Other,15104485.0,
598,400930,6,4,,131275778,5213,Active,,,41.0,IC50,Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity after 44 hrs by MTT assay relative to control,Confirmatory,15104485.0,
599,401471,3,7,,131275778,5213,Unspecified,,,,,Antihepatotoxic activity against 1.5 hrs galactosamine pretreatment-induced cytotoxicity in Wistar rat hepatocytes assessed as glutamic-pyruvic transaminase activity at 0.01 mg/ml after 30 hrs relative to control,Other,6677713.0,
600,401472,3,7,,131275778,5213,Unspecified,,,,,Antihepatotoxic activity against 1.5 hrs galactosamine pretreatment-induced cytotoxicity in Wistar rat hepatocytes assessed as glutamic-pyruvic transaminase activity at 0.1 mg/ml after 30 hrs relative to control,Other,6677713.0,
601,401473,3,7,,131275778,5213,Unspecified,,,,,Antihepatotoxic activity against 1.5 hrs galactosamine pretreatment-induced cytotoxicity in Wistar rat hepatocytes assessed as glutamic-pyruvic transaminase activity at 1 mg/ml after 30 hrs relative to control,Other,6677713.0,
602,401474,8,1,,131275778,5213,Unspecified,,,,,Cytotoxicity in Wistar rat hepatocytes assessed as glutamic-pyruvic transaminase activity at 0.01 mg/ml after 30 hrs,Other,6677713.0,
603,401475,8,1,,131275778,5213,Unspecified,,,,,Cytotoxicity in Wistar rat hepatocytes assessed as glutamic-pyruvic transaminase activity at 0.1 mg/ml after 30 hrs,Other,6677713.0,
604,401476,8,1,,131275778,5213,Unspecified,,,,,Cytotoxicity in Wistar rat hepatocytes assessed as glutamic-pyruvic transaminase activity at 1 mg/ml after 30 hrs,Other,6677713.0,
605,403198,3,6,,131275778,5213,Unspecified,,,,,Antihepatotoxic activity against CCl4-induced cytotoxicity in rat hepatocytes assessed as blockade of glutamic pyruvic transaminase release at 25 uM by Reitman-Frankel method relative to control,Other,9090870.0,
606,403199,3,6,,131275778,5213,Unspecified,,,,,Antihepatotoxic activity against CCl4-induced cytotoxicity in rat hepatocytes assessed as blockade of sorbitol dehydrogenase release at 25 uM by modified Gerlach method relative to control,Other,9090870.0,
607,404304,3,10,,131275778,5213,Unspecified,308153583.0,1244.0,,,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,Other,18457386.0,
608,424718,7,1,,131275778,5213,Unspecified,109940048.0,280960.0,,Km,Activity at bovine xanthine oxidase at 10 uM,Confirmatory,19388706.0,
609,424719,7,1,,131275778,5213,Unspecified,109940048.0,280960.0,,Km,Activity at bovine xanthine oxidase at 25 uM,Confirmatory,19388706.0,
610,424720,7,1,,131275778,5213,Unspecified,109940048.0,280960.0,,Km,Activity at bovine xanthine oxidase at 50 uM,Confirmatory,19388706.0,
611,424721,7,1,,131275778,5213,Unspecified,109940048.0,280960.0,,Km,Activity at bovine xanthine oxidase at 25 uM preincubated for 10 mins,Confirmatory,19388706.0,
612,424722,7,1,,131275778,5213,Unspecified,109940048.0,280960.0,,,Ratio of kcat to km for bovine xanthine oxidase at 10 uM,Other,19388706.0,
613,424723,7,1,,131275778,5213,Unspecified,109940048.0,280960.0,,,Ratio of kcat to km for bovine xanthine oxidase at 25 uM,Other,19388706.0,
614,424724,7,1,,131275778,5213,Unspecified,109940048.0,280960.0,,,Ratio of kcat to km for bovine xanthine oxidase at 50 uM,Other,19388706.0,
615,424725,7,1,,131275778,5213,Unspecified,109940048.0,280960.0,,,Ratio of kcat to km for bovine xanthine oxidase at 25 uM preincubated for 10 mins,Other,19388706.0,
616,424727,7,1,,131275778,5213,Unspecified,109940048.0,280960.0,,,Inhibition of bovine xanthine oxidase assessed as reduction of cytochrome c at 10 uM,Other,19388706.0,
617,424728,7,1,,131275778,5213,Unspecified,109940048.0,280960.0,,,Inhibition of bovine xanthine oxidase assessed as reduction of cytochrome c at 20 uM,Other,19388706.0,
618,424729,7,1,,131275778,5213,Unspecified,109940048.0,280960.0,,,Inhibition of bovine xanthine oxidase assessed as reduction of cytochrome c at 50 uM,Other,19388706.0,
619,424730,7,1,,131275778,5213,Unspecified,109940048.0,280960.0,,,Inhibition of bovine xanthine oxidase assessed as reduction of cytochrome c at 25 uM preincubated for 10 mins,Other,19388706.0,
620,424731,3,10,,131275778,5213,Unspecified,109940048.0,280960.0,,,Inhibition of bovine xanthine oxidase assessed as reduction in xanthine turnover at 10 uM,Other,19388706.0,
621,424732,3,10,,131275778,5213,Unspecified,109940048.0,280960.0,,,Inhibition of bovine xanthine oxidase assessed as reduction in xanthine turnover at 25 uM,Other,19388706.0,
622,424733,3,10,,131275778,5213,Unspecified,109940048.0,280960.0,,,Inhibition of bovine xanthine oxidase assessed as reduction in xanthine turnover at 50 uM,Other,19388706.0,
623,424738,3,10,,131275778,5213,Unspecified,109940048.0,280960.0,,,Ratio of kcat to km for bovine xanthine oxidase at 25 uM preincubated for 10 mins relative to control,Other,19388706.0,
624,424739,3,10,,131275778,5213,Unspecified,109940048.0,280960.0,,,Inhibition of bovine xanthine oxidase assessed as decrease in production of superoxide at 50 uM relative to control,Other,19388706.0,
625,427868,6,2,,131275778,5213,Unspecified,,,75.7,EC50,Hepatoprotective activity against nitrofurantoin-induced cytotoxicity in human HepG2 cells after 2 hrs by MTT assay,Confirmatory,19489592.0,
626,434955,1,2,,855643,5213,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
627,434962,1,2,,855643,5213,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
628,434973,1,3,,855643,5213,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
629,434989,1,1,,855643,5213,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
630,435003,1,3,,855643,5213,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
631,435005,1,1,,855643,5213,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Beta Cell Apoptosis.,Screening,,
632,435022,2,2,,855643,5213,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
633,435030,1,2,,855643,5213,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
634,435030,1,2,,855643,5213,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
635,449291,5,2,,131275778,5213,Unspecified,,,84.8,IC50,Inhibition of lipid peroxidation in Sprague-Dawley rat liver homogenate assessed as malondialdehyde formation after 1 hr by TBARS assay,Confirmatory,19673490.0,
636,449301,8,5,,131275778,5213,Unspecified,1351440.0,497811.0,80.3,IC50,Inhibition of rat liver xanthine oxidase after 2 hrs by spectrophotometry,Confirmatory,19673490.0,
637,449302,4,9,,131275778,5213,Inactive,1351440.0,497811.0,,,Inhibition of rat liver xanthine oxidase at 75 uM after 2 hrs by spectrophotometry,Other,19673490.0,
638,449728,1,2,,855643,5213,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
639,449739,1,2,,855643,5213,Inactive,53832009.0,8912.0,,,Inhibitors of Cav3 T-type Calcium Channels: Primary Screen,Screening,,
640,449762,1,2,,855643,5213,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
641,449763,1,3,,855643,5213,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
642,449768,1,1,,855643,5213,Inactive,7108463.0,6531.0,,,High Throughput Screening for Cocaine Antagonists: Primary Screen,Screening,,
643,450964,3,4,,131275778,5213,Unspecified,,,,,Antioxidant activity assessed as DPPH radical scavenging activity at 100 ug/mL after 30 mins,Other,19660956.0,
644,450965,3,3,,131275778,5213,Unspecified,,,,,Antioxidant activity assessed as superoxide anion scavenging activity at 100 ug/mL after 5 mins by NBT reduction assay,Other,19660956.0,
645,450966,5,2,,131275778,5213,Unspecified,,,196.5,EC50,Antioxidant activity assessed as ferrous ion chelating activity after 30 mins by spectrophotometry,Confirmatory,19660956.0,
646,450967,5,2,,131275778,5213,Active,,,22.7,IC50,Inhibition of FeSO4-induced lipid peroxidation in Sprague-Dawley rat liver homogenate assessed as decrease in malondialdehyde level after 1 hr by TBA assay,Confirmatory,19660956.0,
647,453012,3,5,,131275778,5213,Unspecified,,,,,Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity at 3 uM after 44 hrs by MTT assay relative to untreated control,Other,19775895.0,
648,453013,4,4,,131275778,5213,Unspecified,,,,,Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity at 10 uM after 44 hrs by MTT assay relative to untreated control,Other,19775895.0,
649,453014,4,4,,131275778,5213,Unspecified,,,,,Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity at 30 uM after 44 hrs by MTT assay relative to untreated control,Other,19775895.0,
650,453015,4,4,,131275778,5213,Unspecified,,,,,Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity at 100 uM after 44 hrs by MTT assay relative to untreated control,Other,19775895.0,
651,453017,3,5,,131275778,5213,Unspecified,,,,,Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine/TNFalpha-induced cytotoxicity at 1 uM after 20 hrs by MTT assay relative to untreated control,Other,19775895.0,
652,453018,3,5,,131275778,5213,Unspecified,,,,,Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine/TNFalpha-induced cytotoxicity at 3 uM after 20 hrs by MTT assay relative to untreated control,Other,19775895.0,
653,453019,3,5,,131275778,5213,Unspecified,,,,,Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine/TNFalpha-induced cytotoxicity at 10 uM after 20 hrs by MTT assay relative to untreated control,Other,19775895.0,
654,453020,3,5,,131275778,5213,Unspecified,,,,,Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine/TNFalpha-induced cytotoxicity at 30 uM after 20 hrs by MTT assay relative to untreated control,Other,19775895.0,
655,453021,5,4,,131275778,5213,Active,,,15.0,IC50,Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine/TNFalpha-induced cytotoxicity after 20 hrs by MTT assay relative to untreated control,Confirmatory,19775895.0,
656,458983,3,5,,131275778,5213,Unspecified,,,,,Hepatoprotective activity in ddY mouse primary cultured hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity at 3 ug/mL after 44 hrs by MTT assay,Other,20159656.0,
657,458984,3,5,,131275778,5213,Unspecified,,,,,Hepatoprotective activity in ddY mouse primary cultured hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity at 10 ug/mL after 44 hrs by MTT assay,Other,20159656.0,
658,458985,3,5,,131275778,5213,Unspecified,,,,,Hepatoprotective activity in ddY mouse primary cultured hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity at 30 ug/mL after 44 hrs by MTT assay,Other,20159656.0,
659,458986,3,5,,131275778,5213,Unspecified,,,,,Hepatoprotective activity in ddY mouse primary cultured hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity at 100 ug/mL after 44 hrs by MTT assay,Other,20159656.0,
660,458987,5,4,,131275778,5213,Active,,,38.8,IC50,Hepatoprotective activity in ddY mouse primary cultured hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity after 44 hrs by MTT assay,Confirmatory,20159656.0,
661,458988,4,3,,131275778,5213,Unspecified,,,,,Cytoprotective activity in mouse L929 cells assessed as inhibition of TNF-alpha-induced cytotoxicity at 3 ug/mL after 44 hrs by MTT assay,Other,20159656.0,
662,458989,3,4,,131275778,5213,Unspecified,,,,,Cytoprotective activity in mouse L929 cells assessed as inhibition of TNF-alpha-induced cytotoxicity at 10 ug/mL after 44 hrs by MTT assay,Other,20159656.0,
663,458990,3,4,,131275778,5213,Unspecified,,,,,Cytoprotective activity in mouse L929 cells assessed as inhibition of TNF-alpha-induced cytotoxicity at 30 ug/mL after 44 hrs by MTT assay,Other,20159656.0,
664,458991,3,4,,131275778,5213,Unspecified,,,,,Cytoprotective activity in mouse L929 cells assessed as inhibition of TNF-alpha-induced cytotoxicity at 100 ug/mL after 44 hrs by MTT assay,Other,20159656.0,
665,458992,6,2,,131275778,5213,Unspecified,,,,,Cytoprotective activity in mouse L929 cells assessed as inhibition of TNF-alpha-induced cytotoxicity after 44 hrs by MTT assay,Other,20159656.0,
666,462333,3,3,,131275778,5213,Unspecified,,,,,Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells at 30 uM after 72 hrs,Other,20189399.0,
667,462334,3,3,,131275778,5213,Unspecified,,,,,Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells at 10 uM after 72 hrs,Other,20189399.0,
668,462335,3,3,,131275778,5213,Unspecified,,,,,Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells at 3 uM after 72 hrs,Other,20189399.0,
669,462336,3,3,,131275778,5213,Unspecified,,,,,Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells at 1 uM after 72 hrs,Other,20189399.0,
670,462338,5,2,,131275778,5213,Active,,,21.0,IC50,Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells after 72 hrs,Confirmatory,20189399.0,
671,462339,3,3,,131275778,5213,Unspecified,,,,,Toxicity in mouse B16-4A5 cells assessed as inhibition of cell proliferation at 1 uM in presence of 1 mM theophylline after 72 hrs by WST8 dye reduction assay,Other,20189399.0,
672,462340,4,2,,131275778,5213,Unspecified,,,,,Toxicity in mouse B16-4A5 cells assessed as inhibition of cell proliferation at 3 uM in presence of 1 mM theophylline after 72 hrs by WST8 dye reduction assay,Other,20189399.0,
673,462341,4,2,,131275778,5213,Unspecified,,,,,Toxicity in mouse B16-4A5 cells assessed as inhibition of cell proliferation at 10 uM in presence of 1 mM theophylline after 72 hrs by WST8 dye reduction assay,Other,20189399.0,
674,462342,3,3,,131275778,5213,Unspecified,,,,,Toxicity in mouse B16-4A5 cells assessed as inhibition of cell proliferation at 30 uM in presence of 1 mM theophylline after 72 hrs by WST8 dye reduction assay,Other,20189399.0,
675,462343,5,2,,131275778,5213,Unspecified,,,100.0,IC50,Toxicity in mouse B16-4A5 cells assessed as inhibition of cell proliferation in presence of 1 mM theophylline after 72 hrs by WST8 dye reduction assay,Confirmatory,20189399.0,
676,462344,3,10,,131275778,5213,Unspecified,6686057.0,,,,Inhibition of mushroom tyrosinase at 1 uM,Other,20189399.0,
677,462345,3,10,,131275778,5213,Unspecified,6686057.0,,,,Inhibition of mushroom tyrosinase at 3 uM,Other,20189399.0,
678,462346,3,10,,131275778,5213,Unspecified,6686057.0,,,,Inhibition of mushroom tyrosinase at 10 uM,Other,20189399.0,
679,462347,3,10,,131275778,5213,Unspecified,6686057.0,,,,Inhibition of mushroom tyrosinase at 30 uM,Other,20189399.0,
680,462348,3,10,,131275778,5213,Unspecified,6686057.0,,,,Inhibition of mushroom tyrosinase at 100 uM,Other,20189399.0,
681,462350,3,3,,131275778,5213,Unspecified,,,,,Effect on tyrosinase mRNA expression in mouse B16-4A5 cells assessed as tyrosinase mRNA/beta-actin mRNA expression ratio at 3 uM in presence of 1 mM theophylline after 72 hrs by RT-PCR,Other,20189399.0,
682,462353,3,3,,131275778,5213,Unspecified,,,,,Effect on tyrosinase mRNA expression in mouse B16-4A5 cells assessed as tyrosinase mRNA/beta-actin mRNA expression ratio at 1 uM in presence of 1 mM theophylline after 72 hrs by RT-PCR,Other,20189399.0,
683,462354,3,3,,131275778,5213,Unspecified,,,,,Effect on tyrosinase mRNA expression in mouse B16-4A5 cells assessed as tyrosinase mRNA/beta-actin mRNA expression ratio at 10 uM in presence of 1 mM theophylline after 72 hrs by RT-PCR,Other,20189399.0,
684,462355,3,3,,131275778,5213,Unspecified,,,,,Effect on tyrosinase mRNA expression in mouse B16-4A5 cells assessed as tyrosinase mRNA/beta-actin mRNA expression ratio at 30 uM in presence of 1 mM theophylline after 72 hrs by RT-PCR,Other,20189399.0,
685,462356,3,3,,131275778,5213,Unspecified,,,,,Effect on TRP1 mRNA expression in mouse B16-4A5 cells assessed as TRP1 mRNA/beta-actin mRNA expression ratio at 1 uM in presence of 1 mM theophylline after 72 hrs by RT-PCR,Other,20189399.0,
686,462357,3,3,,131275778,5213,Unspecified,,,,,Effect on TRP1 mRNA expression in mouse B16-4A5 cells assessed as TRP1 mRNA/beta-actin mRNA expression ratio at 3 uM in presence of 1 mM theophylline after 72 hrs by RT-PCR,Other,20189399.0,
687,462358,3,3,,131275778,5213,Unspecified,,,,,Effect on TRP1 mRNA expression in mouse B16-4A5 cells assessed as TRP1 mRNA/beta-actin mRNA expression ratio at 10 uM in presence of 1 mM theophylline after 72 hrs by RT-PCR,Other,20189399.0,
688,462359,3,3,,131275778,5213,Unspecified,,,,,Effect on TRP1 mRNA expression in mouse B16-4A5 cells assessed as TRP1 mRNA/beta-actin mRNA expression ratio at 30 uM in presence of 1 mM theophylline after 72 hrs by RT-PCR,Other,20189399.0,
689,462360,3,3,,131275778,5213,Unspecified,,,,,Effect on TRP2 mRNA expression in mouse B16-4A5 cells assessed as TRP2 mRNA/beta-actin mRNA expression ratio at 1 uM in presence of 1 mM theophylline after 72 hrs by RT-PCR,Other,20189399.0,
690,462361,3,3,,131275778,5213,Unspecified,,,,,Effect on TRP2 mRNA expression in mouse B16-4A5 cells assessed as TRP2 mRNA/beta-actin mRNA expression ratio at 3 uM in presence of 1 mM theophylline after 72 hrs by RT-PCR,Other,20189399.0,
691,462362,3,3,,131275778,5213,Unspecified,,,,,Effect on TRP2 mRNA expression in mouse B16-4A5 cells assessed as TRP2 mRNA/beta-actin mRNA expression ratio at 10 uM in presence of 1 mM theophylline after 72 hrs by RT-PCR,Other,20189399.0,
692,462363,3,3,,131275778,5213,Unspecified,,,,,Effect on TRP2 mRNA expression in mouse B16-4A5 cells assessed as TRP2 mRNA/beta-actin mRNA expression ratio at 30 uM in presence of 1 mM theophylline after 72 hrs by RT-PCR,Other,20189399.0,
693,462365,4,5,,131275778,5213,Active,52001076.0,26413.0,,,Inhibition of ERK1/2 phosphorylation in mouse B16-4A5 cells at 100 uM in presence of 1 mM theophylline after 72 hrs by immunoblot,Other,20189399.0,
694,462365,4,5,,131275778,5213,Active,52001483.0,26417.0,,,Inhibition of ERK1/2 phosphorylation in mouse B16-4A5 cells at 100 uM in presence of 1 mM theophylline after 72 hrs by immunoblot,Other,20189399.0,
695,462367,4,9,,131275778,5213,Inactive,6686057.0,,,,Inhibition of mushroom tyrosinase assessed as inhibition of melanin production from dopachrome by autoxidation at 100 uM,Other,20189399.0,
696,463075,1,1,,855643,5213,Inactive,,,,,HTS to identify inhibitors of TNF-alpha Induced Cell Death in Jurkat FADD-/- Cells.,Screening,,
697,463079,1,2,,855643,5213,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
698,463082,1,1,,855643,5213,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
699,463104,1,2,,855643,5213,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
700,463111,1,1,,855643,5213,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4),Screening,,
701,463115,1,1,,855643,5213,Inactive,119622516.0,5045.0,,,High throughput fluorescence intensity-based biochemical assay to screen for small molecule inhibitors of Furin conducted by the Pittsburgh Molecular Library Screening Center.,Screening,,
702,463141,1,2,,855643,5213,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
703,463165,1,1,,855643,5213,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of   G-protein signaling 4 (RGS4),Screening,,
704,463187,1,1,,855643,5213,Inactive,,,,,384-well Z-Lyte format Hck-Nef inhibitor HTS run at the PMLSC,Screening,,
705,463189,1,1,,855643,5213,Inactive,,,,,96-well format Chlamydomonas reinhardtii Algae Gravitaxis Assay to measure the difference in the absorbance between the small compact plug of WT swimming algae versus the MUT algae lacking cilia.,Screening,,
706,463190,1,2,,855643,5213,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
707,463193,1,1,,855643,5213,Inactive,31563518.0,84557.0,,,High-content cell-based screening for modulators of autophagy,Screening,,
708,463195,1,2,,855643,5213,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
709,463210,1,2,,855643,5213,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
710,463212,1,1,,855643,5213,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
711,463254,1,1,,855643,5213,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
712,464222,5,4,,131275778,5213,Unspecified,,,58.1,IC50,Antioxidant activity in Wistar rat liver microsomes assessed as inhibition of lipid peroxidation after 1 hr by thiobarbiturate color reaction,Confirmatory,20036447.0,
713,464223,5,3,,131275778,5213,Unspecified,,,2100.0,IC50,Antioxidant activity assessed as DPPH radical scavenging activity for 10 mins,Confirmatory,20036447.0,
714,464224,5,2,,131275778,5213,Unspecified,,,800.0,CC50,Cytotoxicity against MDCK cells after 2 hrs by MTT assay,Confirmatory,20036447.0,
715,464225,5,2,,131275778,5213,Inconclusive,,,,EC50,Antiviral activity against Influenza A virus (A/PR8/34(H1N1)) infected in MDCK cells assessed as inhibition of plaque formation,Confirmatory,20036447.0,
716,485270,1,1,,855643,5213,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
717,485272,1,1,,855643,5213,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
718,485273,2,1,,855643,5213,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
719,485275,1,3,,855643,5213,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
720,485281,1,1,,855643,5213,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
721,485290,1,1,,855643,5213,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
722,485290,1,1,,26747209,5213,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
723,485294,1,1,,855643,5213,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
724,485297,1,1,,855643,5213,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
725,485298,1,1,,855643,5213,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
726,485313,1,2,,855643,5213,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
727,485314,1,1,,855643,5213,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
728,485317,1,2,,855643,5213,Inactive,54112432.0,2671.0,,,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,Screening,,
729,485341,1,1,,855643,5213,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
730,485344,1,1,,855643,5213,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,Screening,,
731,485346,1,1,,855643,5213,Inactive,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
732,485346,1,1,,855643,5213,Inactive,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
733,485347,1,2,,855643,5213,Inactive,4503385.0,1813.0,,,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,Screening,,
734,485349,1,1,,855643,5213,Inactive,71902540.0,472.0,,Potency,qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia,Confirmatory,,
735,485350,1,2,,92221971,5213,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
736,485353,2,1,,855643,5213,Inactive,30124074.0,1489680.0,,,qHTS of Yeast-based Assay for SARS-CoV PLP,Confirmatory,,
737,485358,1,1,,855643,5213,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists,Screening,,
738,485360,1,1,,855643,5213,Inactive,117938328.0,26013.0,,Potency,qHTS Assay for the Inhibitors of L3MBTL1,Confirmatory,,
739,485364,1,1,,855643,5213,Inactive,15149312.0,8345881.0,,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
740,485367,1,2,,855643,5213,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
741,485395,1,2,,92221971,5213,Inactive,150392496.0,,,,A screen for compounds that inhibit the activity of Staphylococcus aureus DNA helicase,Other,,
742,488837,1,1,,855643,5213,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
743,488839,1,1,,855643,5213,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
744,488839,1,1,,855643,5213,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
745,488847,1,3,,855643,5213,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
746,488862,1,1,,855643,5213,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
747,488890,1,2,,855643,5213,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
748,488895,1,2,,855643,5213,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
749,488896,1,1,,855643,5213,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
750,488899,1,1,,855643,5213,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
751,488922,1,2,,855643,5213,Inactive,7706135.0,,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9,Screening,,
752,488965,1,2,,855643,5213,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
753,488966,1,1,,855643,5213,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
754,488975,1,2,,855643,5213,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
755,488977,1,2,,855643,5213,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
756,489030,2,1,,855643,5213,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
757,489031,2,1,,855643,5213,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
758,492947,1,1,,855643,5213,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
759,492953,1,1,,855643,5213,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
760,492956,1,1,,855643,5213,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
761,492967,1,2,,92221971,5213,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
762,492972,1,1,,855643,5213,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
763,493005,1,1,,855643,5213,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
764,493008,1,1,,855643,5213,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
765,493008,1,1,,855643,5213,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
766,493008,1,1,,855643,5213,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
767,493008,1,1,,855643,5213,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
768,493011,1,1,,855643,5213,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
769,493012,1,1,,855643,5213,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
770,493014,1,1,,855643,5213,Inactive,,,,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
771,493033,1,2,,92221971,5213,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
772,493036,1,2,,855643,5213,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
773,493056,1,1,,855643,5213,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
774,493084,1,1,,855643,5213,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
775,493087,1,1,,855643,5213,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
776,493091,1,1,,855643,5213,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
777,493098,1,1,,855643,5213,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
778,493131,1,1,,855643,5213,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
779,493160,1,1,,855643,5213,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
780,493187,1,2,,855643,5213,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
781,493244,1,1,,855643,5213,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
782,493244,1,1,,855643,5213,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
783,493244,1,1,,855643,5213,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
784,493244,1,1,,855643,5213,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
785,501903,7,5,,131275778,5213,Active,115449.0,759.0,1.49,Ki,Inhibition of human carbonic anhydrase 1 after 15 mins by stopped flow CO2 hydration method,Confirmatory,20674354.0,
786,501904,7,5,,131275778,5213,Active,115456.0,760.0,2.51,Ki,Inhibition of human carbonic anhydrase 2 after 15 mins by stopped flow CO2 hydration method,Confirmatory,20674354.0,
787,501905,7,5,,131275778,5213,Active,134047703.0,761.0,6.43,Ki,Inhibition of human carbonic anhydrase 3 after 15 mins by stopped flow CO2 hydration method,Confirmatory,20674354.0,
788,501906,7,5,,131275778,5213,Active,115465.0,762.0,8.96,Ki,Inhibition of human carbonic anhydrase 4 after 15 mins by stopped flow CO2 hydration method,Confirmatory,20674354.0,
789,501907,7,5,,131275778,5213,Active,461680.0,763.0,4.08,Ki,Inhibition of human carbonic anhydrase 5a after 15 mins by stopped flow CO2 hydration method,Confirmatory,20674354.0,
790,501908,7,5,,131275778,5213,Active,8928041.0,11238.0,4.56,Ki,Inhibition of human carbonic anhydrase 5b after 15 mins by stopped flow CO2 hydration method,Confirmatory,20674354.0,
791,501909,7,5,,131275778,5213,Active,116241278.0,765.0,9.7,Ki,Inhibition of human carbonic anhydrase 6 after 15 mins by stopped flow CO2 hydration method,Confirmatory,20674354.0,
792,501910,7,5,,131275778,5213,Active,1168744.0,766.0,4.71,Ki,Inhibition of human carbonic anhydrase 7 after 15 mins by stopped flow CO2 hydration method,Confirmatory,20674354.0,
793,501912,7,5,,131275778,5213,Active,5915866.0,771.0,9.05,Ki,Inhibition of human carbonic anhydrase 12 after 15 mins by stopped flow CO2 hydration method,Confirmatory,20674354.0,
794,501913,7,5,,131275778,5213,Active,30580350.0,377677.0,4.82,Ki,Inhibition of human carbonic anhydrase 13 after 15 mins by stopped flow CO2 hydration method,Confirmatory,20674354.0,
795,501914,7,5,,131275778,5213,Active,8928036.0,23632.0,11.64,Ki,Inhibition of human carbonic anhydrase 14 after 15 mins by stopped flow CO2 hydration method,Confirmatory,20674354.0,
796,501915,7,5,,131275778,5213,Active,30580362.0,80733.0,0.65,Ki,Inhibition of mouse carbonic anhydrase 15 after 15 mins by stopped flow CO2 hydration method,Confirmatory,20674354.0,
797,502077,7,5,,131275778,5213,Active,83300925.0,768.0,10.15,Ki,Inhibition of human carbonic anhydrase 9 after 15 mins by stopped flow CO2 hydration method,Confirmatory,20674354.0,
798,504326,1,2,,855643,5213,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
799,504326,1,2,,855643,5213,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
800,504327,1,1,,855643,5213,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
801,504329,1,1,,855643,5213,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
802,504332,1,1,,855643,5213,Active,168985070.0,,50.1187,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
803,504333,1,1,,855643,5213,Inactive,6683500.0,29994.0,,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
804,504339,1,1,,855643,5213,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
805,504357,1,1,,855643,5213,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
806,504357,1,1,,855643,5213,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
807,504406,1,1,,855643,5213,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
808,504408,2,1,,855643,5213,Inactive,,,,,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,Screening,,
809,504411,1,1,,855643,5213,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
810,504414,1,1,,855643,5213,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
811,504414,1,1,,855643,5213,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
812,504423,1,1,,855643,5213,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
813,504441,1,1,,855643,5213,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
814,504444,1,1,,855643,5213,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
815,504454,1,3,,855643,5213,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
816,504462,1,1,,855643,5213,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
817,504466,1,1,,855643,5213,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
818,504467,1,1,,855643,5213,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
819,504490,1,2,,855643,5213,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
820,504523,1,1,,855643,5213,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
821,504523,1,1,,855643,5213,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
822,504558,1,1,,855643,5213,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
823,504577,2,2,,855643,5213,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
824,504582,2,1,,855643,5213,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
825,504621,1,1,,855643,5213,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
826,504634,1,1,,855643,5213,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
827,504648,1,1,,855643,5213,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
828,504651,1,1,,855643,5213,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
829,504652,1,1,,855643,5213,Inactive,4503383.0,1812.0,,,Antagonist of Human D 1 Dopamine Receptor: qHTS,Screening,,
830,504660,1,1,,855643,5213,Inactive,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
831,504690,1,3,,855643,5213,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
832,504692,2,2,,855643,5213,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
833,504700,1,1,,855643,5213,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
834,504700,1,1,,855643,5213,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
835,504706,1,1,,855643,5213,Inactive,23491729.0,7157.0,,Potency,qHTS assay for re-activators of p53 using a Luc reporter,Confirmatory,,
836,504707,1,1,,855643,5213,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
837,504707,1,1,,855643,5213,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
838,504720,1,1,,855643,5213,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
839,504734,1,1,,855643,5213,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
840,504766,2,1,,855643,5213,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
841,504770,1,2,,92221971,5213,Inactive,9657380.0,2612528.0,,,A screen for compounds that inhibit replication of Vibrio cholerae chromosome II,Other,,
842,504775,1,1,,855643,5213,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
843,504803,1,1,,855643,5213,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
844,504810,1,2,,855643,5213,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
845,504812,1,2,,855643,5213,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
846,504832,1,1,,855643,5213,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
847,504834,1,1,,855643,5213,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
848,504842,1,1,,855643,5213,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
849,504845,1,1,,855643,5213,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
850,504847,1,1,,855643,5213,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
851,504884,1,2,,855643,5213,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
852,504891,1,1,,855643,5213,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
853,504894,1,1,,855643,5213,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
854,504937,1,2,,855643,5213,Inconclusive,179095.0,6609.0,100.0,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
855,540253,1,1,,855643,5213,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
856,540253,1,1,,855643,5213,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
857,540253,1,1,,855643,5213,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
858,540256,1,2,,855643,5213,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
859,540263,1,1,,855643,5213,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
860,540263,1,1,,855643,5213,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
861,540267,1,1,,855643,5213,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
862,540275,1,1,,855643,5213,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
863,540276,1,2,,855643,5213,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
864,540277,1,1,,855643,5213,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
865,540295,1,1,,855643,5213,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
866,540299,1,2,,92221971,5213,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
867,540303,1,1,,855643,5213,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
868,540303,1,1,,855643,5213,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
869,540303,1,1,,855643,5213,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
870,540308,1,1,,855643,5213,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
871,540317,1,1,,855643,5213,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
872,540336,1,1,,855643,5213,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
873,540336,1,1,,855643,5213,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
874,540364,1,2,,855643,5213,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
875,588211,2,3,,131275778,5213,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
876,588212,2,3,,131275778,5213,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
877,588213,2,3,,131275778,5213,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
878,588334,1,1,,855643,5213,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
879,588335,1,1,,855643,5213,Active,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
880,588342,1,1,,855643,5213,Inactive,160794.0,,,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
881,588352,1,2,,855643,5213,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
882,588354,1,1,,855643,5213,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
883,588358,1,2,,855643,5213,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
884,588391,1,1,,855643,5213,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
885,588405,1,1,,855643,5213,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
886,588413,1,2,,855643,5213,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
887,588436,1,1,,855643,5213,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
888,588453,1,1,,855643,5213,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
889,588456,1,1,,855643,5213,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
890,588458,1,1,,855643,5213,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
891,588473,1,1,,855643,5213,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
892,588473,1,1,,855643,5213,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
893,588475,1,2,,855643,5213,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
894,588475,1,2,,855643,5213,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
895,588478,1,2,,124800321,5213,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
896,588489,1,1,,855643,5213,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
897,588492,1,1,,855643,5213,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
898,588493,1,2,,855643,5213,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
899,588497,1,2,,855643,5213,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
900,588497,1,2,,855643,5213,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
901,588497,1,2,,855643,5213,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
902,588499,1,3,,855643,5213,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
903,588499,1,3,,855643,5213,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
904,588499,1,3,,855643,5213,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
905,588501,1,2,,855643,5213,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
906,588501,1,2,,855643,5213,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
907,588501,1,2,,855643,5213,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
908,588511,1,2,,855643,5213,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
909,588519,1,2,,92221971,5213,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
910,588549,1,1,,855643,5213,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
911,588579,1,1,,855643,5213,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
912,588579,1,1,,124883412,5213,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
913,588590,1,1,,855643,5213,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
914,588591,1,1,,855643,5213,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
915,588621,1,1,,855643,5213,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
916,588627,1,1,,855643,5213,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
917,588664,1,2,,855643,5213,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
918,588664,1,2,,855643,5213,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
919,588674,1,2,,855643,5213,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
920,588675,1,1,,855643,5213,Active,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
921,588676,1,1,,855643,5213,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
922,588689,1,1,,855643,5213,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
923,588692,2,1,,855643,5213,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
924,588726,1,2,,855643,5213,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
925,588727,1,1,,855643,5213,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
926,588795,1,1,,855643,5213,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
927,588814,1,3,,855643,5213,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
928,588819,1,4,,855643,5213,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
929,588850,1,1,,855643,5213,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
930,588852,1,3,,855643,5213,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
931,588855,1,1,,855643,5213,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
932,588856,1,1,,855643,5213,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
933,589083,3,7,,131275778,5213,Unspecified,6686268.0,1559.0,,Ki,Mechanism based inhibition of human cytochrome P450 2C9 measured by 7-EFC O-deethylation,Confirmatory,16248836.0,
934,589119,3,7,,131275778,5213,Unspecified,116241312.0,1576.0,,Ki,Mechanism based inhibition of human cytochrome P450 3A4 measured by BFC hydroxylation,Confirmatory,16248836.0,
935,589150,3,7,,131275778,5213,Unspecified,116241312.0,1576.0,,Ki,Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation,Confirmatory,16248836.0,
936,592713,2,4,,131275778,5213,Active,,,,,Hepatoprotective activity in human HepG2 cells assessed as inhibition of CCl4-induced toxicity at 100 uM after 24 hrs by MTT assay,Other,21459003.0,
937,592714,4,2,,131275778,5213,Unspecified,,,,IC50,Cytotoxicity against human HepG2 cells after 24 hrs assessed as inhibition of cell viability by MTT assay,Confirmatory,21459003.0,
938,592715,3,2,,131275778,5213,Active,,,45.0,EC50,Hepatoprotective activity in human HepG2 cells assessed as inhibition of CCl4-induced toxicity after 24 hrs by MTT assay,Confirmatory,21459003.0,
939,592721,3,2,,131275778,5213,Unspecified,,,,IC50,Cytotoxicity against rat HSC-T6 cell after 24 hrs by MTT assay,Confirmatory,21459003.0,
940,592722,3,2,,131275778,5213,Active,,,18.83,EC50,Antiproliferative activity against serum-stimulated rat HSC-T6 cells after 24 hrs by MTT assay,Confirmatory,21459003.0,
941,592724,1,4,,131275778,5213,Unspecified,,,,,Hepatoprotective activity in human HepG2 cells assessed as protection against cell damage after 24 hrs by MTT assay,Other,21459003.0,
942,592725,1,4,,131275778,5213,Unspecified,,,,,Cytotoxicity against rat HSC-T6 cell up to 300 uM after 24 hrs by MTT assay,Other,21459003.0,
943,595265,2,5,,131275778,5213,Active,17865718.0,3326.0,,,Inhibition of Hsp90 in human MCF7 cells assessed as Her2 degradation at 50 to 1000 uM by Western blot analysis,Other,21273068.0,
944,595265,2,5,,131275778,5213,Active,92090606.0,3320.0,,,Inhibition of Hsp90 in human MCF7 cells assessed as Her2 degradation at 50 to 1000 uM by Western blot analysis,Other,21273068.0,
945,595266,2,5,,131275778,5213,Active,17865718.0,3326.0,,,Inhibition of Hsp90 in human MCF7 cells assessed as Hsp90 degradation at 50 to 1000 uM by Western blot analysis,Other,21273068.0,
946,595266,2,5,,131275778,5213,Active,92090606.0,3320.0,,,Inhibition of Hsp90 in human MCF7 cells assessed as Hsp90 degradation at 50 to 1000 uM by Western blot analysis,Other,21273068.0,
947,595267,2,5,,131275778,5213,Active,17865718.0,3326.0,,,Inhibition of Hsp90 in human MCF7 cells assessed as Raf degradation at 50 to 1000 uM by Western blot analysis,Other,21273068.0,
948,595267,2,5,,131275778,5213,Active,92090606.0,3320.0,,,Inhibition of Hsp90 in human MCF7 cells assessed as Raf degradation at 50 to 1000 uM by Western blot analysis,Other,21273068.0,
949,595268,2,5,,131275778,5213,Active,17865718.0,3326.0,,,Inhibition of Hsp90 in human MCF7 cells assessed as Akt degradation at 50 to 1000 uM by Western blot analysis,Other,21273068.0,
950,595268,2,5,,131275778,5213,Active,92090606.0,3320.0,,,Inhibition of Hsp90 in human MCF7 cells assessed as Akt degradation at 50 to 1000 uM by Western blot analysis,Other,21273068.0,
951,595270,2,10,,131275778,5213,Unspecified,218512076.0,,,,Inhibition of Hsp90-dependent activation of [35S]-labeled His-tagged eIF2alpha in rabbit reticulocyte lysate by anti-His-tag pull down assay,Other,21273068.0,
952,595296,2,10,,131275778,5213,Active,218512076.0,,,,Inhibition of Hsp90-dependent maturation of [35S]-labeled His-tagged eIF2alpha in rabbit reticulocyte lysate at 2 mM by anti-His-tag pull down assay,Other,21273068.0,
953,595300,1,5,,131275778,5213,Unspecified,,,,,Antiproliferative activity against estrogen receptor-deficient human SKBR3 cells expressing HER2,Other,21273068.0,
954,595301,1,4,,131275778,5213,Unspecified,,,,,Antiproliferative activity against human MCF7 cells expressing estrogen receptor,Other,21273068.0,
955,595302,2,4,,131275778,5213,Inactive,,,,,Inhibition of Hsp90/Cdc37 interaction with [35S]-labeled His-tagged eIF2alpha in rabbit reticulocyte lysate at 2 mM by Western blot analysis,Other,21273068.0,
956,595318,2,10,,131275778,5213,Active,218512076.0,,,,Inhibition of Hsp90-dependent activation of [35S]-labeled His-tagged eIF2alpha in rabbit reticulocyte lysate at 2 mM by anti-His-tag pull down assay,Other,21273068.0,
957,602123,1,1,,855643,5213,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
958,602141,1,1,,855643,5213,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
959,602162,1,1,,855643,5213,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
960,602163,1,1,,855643,5213,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
961,602179,1,2,,855643,5213,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
962,602229,1,1,,855643,5213,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
963,602233,1,1,,855643,5213,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
964,602244,1,2,,855643,5213,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
965,602247,1,2,,855643,5213,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
966,602248,1,2,,855643,5213,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
967,602250,1,2,,855643,5213,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
968,602252,1,1,,855643,5213,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
969,602252,1,1,,855643,5213,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
970,602261,1,1,,855643,5213,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
971,602274,1,2,,855643,5213,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
972,602276,1,1,,855643,5213,Inactive,20140422.0,7098.0,,,Novel Modifiers of Toll-like and RIG-like Receptor Signaling-SeV Stimulus,Screening,,
973,602277,1,1,,855643,5213,Inactive,20140422.0,7098.0,,,Novel Modifiers of Toll-like and RIG-like Receptor Signaling-Poly IC Stimulus,Screening,,
974,602281,1,1,,855643,5213,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
975,602281,1,1,,855643,5213,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
976,602310,1,2,,855643,5213,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
977,602313,1,1,,855643,5213,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
978,602329,1,1,,855643,5213,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
979,602332,1,1,,855643,5213,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
980,602332,1,1,,124883412,5213,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
981,602340,1,2,,855643,5213,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
982,602342,2,1,,855643,5213,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
983,602346,1,1,,855643,5213,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
984,602363,1,1,,855643,5213,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
985,602393,1,1,,855643,5213,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
986,602396,1,2,,855643,5213,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
987,602399,1,2,,855643,5213,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
988,602405,1,1,,855643,5213,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
989,602410,1,1,,855643,5213,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
990,602429,1,1,,855643,5213,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
991,602438,1,1,,855643,5213,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
992,602440,1,1,,855643,5213,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
993,602449,1,2,,855643,5213,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
994,602481,1,1,,855643,5213,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
995,609842,1,4,,131275778,5213,Active,,,,,"Antioxidant activity in rat immortalized Rat1 cells assessed as inhibition of hydrogen peroxide-induced reactive oxygen species production by measuring conversion of 2',7'-dichlorofluorescin diacetate into 2',7'-dichlorofluorescein at 30 uM treated 48 hrs before H2O2 challenge measured after 15 mins by fluorescence assay",Other,21737270.0,
996,609843,1,3,,131275778,5213,Unspecified,,,,,"Octanol-water partition coefficient, log P of the compound at pH 7.4 by stir-flask method",Other,21737270.0,
997,609844,3,2,,131275778,5213,Unspecified,,,,IC50,Cytotoxicity against rat immortalized Rat1 cells after 48 hrs by MTT assay,Confirmatory,21737270.0,
998,609872,1,4,,131275778,5213,Unspecified,,,,,Cytotoxicity against rat immortalized Rat1 cells assessed as reduction of cell viability at 30 uM after 48 hrs by MTT assay,Other,21737270.0,
999,621925,3,2,,131275778,5213,Unspecified,,,72.58,IC50,Cytotoxicity against HUVEC assessed as cell viability after 16 hrs by MTT assay,Confirmatory,21928794.0,
1000,621928,1,4,,131275778,5213,Unspecified,,,,,Cytotoxicity against HUVEC by LDH release assay,Other,21928794.0,
1001,621929,3,2,,131275778,5213,Active,,,9.99,IC50,Antiproliferative activity against HUVEC assessed as inhibition of cell growth after 3 days by MTT assay,Confirmatory,21928794.0,
1002,621930,4,1,,131275778,5213,Unspecified,,,,,Antiangiogenic activity in HUVEC assessed as inhibition of cell migration after 16 to 20 hrs by wound healing migration assay,Other,21928794.0,
1003,621932,1,5,,131275778,5213,Active,,,,,Antiangiogenic activity in HUVEC assessed as inhibition of tube formation at 75 uM after 6 hrs by Matrigel assay,Other,21928794.0,
1004,621933,4,1,,131275778,5213,Unspecified,,,,,Antiangiogenic activity in HUVEC assessed as inhibition of tube formation after 24 hrs by Matrigel assay,Other,21928794.0,
1005,623870,1,1,,855643,5213,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1006,623870,1,1,,855643,5213,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1007,623877,1,1,,855643,5213,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
1008,623901,1,1,,855643,5213,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
1009,624037,1,3,,855643,5213,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1010,624038,1,3,,855643,5213,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1011,624040,1,3,,855643,5213,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1012,624125,1,4,,855643,5213,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1013,624126,1,3,,855643,5213,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1014,624127,1,2,,855643,5213,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1015,624168,1,1,,855643,5213,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
1016,624169,1,1,,855643,5213,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
1017,624170,1,1,,855643,5213,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
1018,624171,1,1,,855643,5213,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
1019,624172,1,1,,855643,5213,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
1020,624173,1,3,,855643,5213,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
1021,624178,1,1,,855643,5213,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
1022,624202,1,1,,855643,5213,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
1023,624204,1,2,,855643,5213,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
1024,624246,1,1,,855643,5213,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
1025,624256,1,2,,855643,5213,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
1026,624263,1,1,,855643,5213,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1027,624263,1,1,,855643,5213,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1028,624267,1,2,,855643,5213,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1029,624267,1,2,,855643,5213,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1030,624268,1,3,,855643,5213,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
1031,624288,1,1,,855643,5213,Inconclusive,52000961.0,2778.0,35.4813,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
1032,624296,1,1,,855643,5213,Active,7705682.0,51053.0,25.929000000000002,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1033,624297,1,1,,855643,5213,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1034,624304,1,2,,855643,5213,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
1035,624330,1,2,,855643,5213,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
1036,624352,1,1,,855643,5213,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
1037,624354,1,1,,855643,5213,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
1038,624377,1,1,,855643,5213,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
1039,624414,1,1,,855643,5213,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1040,624415,1,2,,855643,5213,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1041,624416,1,1,,855643,5213,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
1042,624417,1,1,,855643,5213,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
1043,624418,1,1,,855643,5213,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
1044,624463,1,1,,855643,5213,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
1045,624464,1,1,,855643,5213,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
1046,624465,1,1,,855643,5213,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
1047,624466,1,3,,855643,5213,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1048,624467,1,1,,855643,5213,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1049,624483,1,1,,855643,5213,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
1050,626784,1,4,,131275778,5213,Unspecified,,,,,"Hepatoprotective activity in ICR mouse assessed as reduction in GalN/LPS-induced mortality at 200 mg/kg, ip administered 1 hr prior to GalN/LPS challenge measured after 24 hrs of GalN/LPS injection",Other,21899269.0,
1051,626962,3,1,,131275778,5213,Unspecified,,,,,Cytotoxicity against human embryo L02 cells assessed as cell viability after 48 hrs by MTT assay,Other,21866900.0,
1052,626964,2,2,,131275778,5213,Unspecified,,,,,Cytoprotective activity in human embryo L02 cells assessed as inhibition of D-galactosamine-induced cytotoxicity at 6.25 ug/ml treated for 1 hr prior to D-galactosamine challenge measured after 48 hrs by MTT assay relative to control,Other,21866900.0,
1053,626965,2,2,,131275778,5213,Unspecified,,,,,Cytoprotective activity in human embryo L02 cells assessed as inhibition of D-galactosamine-induced cytotoxicity at 3.13 ug/ml treated for 1 hr prior to D-galactosamine challenge measured after 48 hrs by MTT assay relative to control,Other,21866900.0,
1054,626966,1,3,,131275778,5213,Unspecified,,,,,Cytoprotective activity in human embryo L02 cells assessed as inhibition of D-galactosamine-induced cytotoxicity at 1.56 ug/ml treated for 1 hr prior to D-galactosamine challenge measured after 48 hrs by MTT assay relative to control,Other,21866900.0,
1055,632214,3,1,,131275778,5213,Unspecified,,,,,"Antihepatotoxic activity against CCl4-induced liver damage in rat assessed as decrease in serum SGOT level at 10 mg/kg, po by calorimetric assay (Rvb = 74.52 +/- 0.695 IU/L)",Other,22061643.0,
1056,632215,3,1,,131275778,5213,Unspecified,,,,,"Antihepatotoxic activity against CCl4-induced liver damage in rat assessed as decrease in serum SGPT level at 10 mg/kg, po by calorimetric assay (Rvb = 85.27 +/- 2.05 IU/L)",Other,22061643.0,
1057,632216,1,3,,131275778,5213,Unspecified,,,,,"Antihepatotoxic activity against CCl4-induced liver damage in rat assessed as decrease in ALP level at 10 mg/kg, po after 1 hr by photoelectric reading analysis (Rvb = 66.157 +/- 2.886 KA)",Other,22061643.0,
1058,632217,1,3,,131275778,5213,Unspecified,,,,,"Antihepatotoxic activity against CCl4-induced liver damage in rat assessed as increase in total protein level at 10 mg/kg, po (Rvb = 3.54 +/- 0.67 g/dl)",Other,22061643.0,
1059,632218,1,3,,131275778,5213,Active,,,,,"Antihepatotoxic effect against CCl4-induced liver damage in rat assessed as appearance of uniformly stained cytoplasm at 10 mg/kg, po by microscopic examination-based histopathological analysis",Other,22061643.0,
1060,632219,1,3,,131275778,5213,Active,,,,,"Antihepatotoxic effect against CCl4-induced liver damage in rat assessed as appearance of mild dilution of sinusoidal spaces at 10 mg/kg, po by microscopic examination-based histopathological analysis",Other,22061643.0,
1061,632220,1,3,,131275778,5213,Active,,,,,"Antihepatotoxic effect against CCl4-induced liver damage in rat assessed as appearance of visible central vein at 10 mg/kg, po by microscopic examination-based histopathological analysis",Other,22061643.0,
1062,632221,1,3,,131275778,5213,Active,,,,,"Antihepatotoxic effect against CCl4-induced liver damage in rat assessed as absence of necrosis at 10 mg/kg, po by microscopic examination-based histopathological analysis",Other,22061643.0,
1063,651550,1,1,,855643,5213,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
1064,651560,1,1,,855643,5213,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
1065,651572,1,2,,855643,5213,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
1066,651582,1,1,,855643,5213,Inactive,,,,,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,Screening,,
1067,651602,1,1,,855643,5213,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1068,651602,1,1,,855643,5213,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1069,651602,1,1,,855643,5213,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1070,651610,2,1,,855643,5213,Inactive,,,,,HIV entry: Env-mediated Cell Fusion Measured in Cell-Based System Using Plate Reader - 7013-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1071,651635,1,3,,855643,5213,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
1072,651636,1,1,,855643,5213,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
1073,651640,1,1,,855643,5213,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
1074,651644,1,1,,855643,5213,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
1075,651647,1,1,,855643,5213,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
1076,651654,1,1,,855643,5213,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1077,651658,1,1,,855643,5213,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1078,651661,2,1,,855643,5213,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1079,651687,1,1,,855643,5213,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1080,651699,1,1,,855643,5213,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1081,651699,1,1,,855643,5213,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1082,651702,1,2,,855643,5213,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
1083,651704,2,1,,855643,5213,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1084,651710,1,1,,855643,5213,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1085,651711,2,1,,855643,5213,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1086,651718,1,2,,855643,5213,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
1087,651719,1,2,,855643,5213,Inactive,4503907.0,8484.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the Galanin Receptor 3 (GalR3),Screening,,
1088,651723,1,1,,855643,5213,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
1089,651724,1,1,,855643,5213,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
1090,651725,1,1,,855643,5213,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
1091,651768,1,2,,855643,5213,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
1092,651800,1,1,,855643,5213,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
1093,651819,1,1,,855643,5213,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
1094,651820,1,1,,855643,5213,Inconclusive,,,10.0,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
1095,651821,2,4,,855643,5213,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
1096,651957,1,1,,855643,5213,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
1097,651958,1,1,,855643,5213,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
1098,651965,1,1,,855643,5213,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
1099,651999,1,1,,855643,5213,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
1100,652010,1,1,,855643,5213,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
1101,652017,1,1,,855643,5213,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
1102,652025,1,1,,855643,5213,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
1103,652029,1,2,,92709227,5213,Active,9966764.0,11313.0,,,Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: Fluorescence-based biochemical gel-based ABPP inhibition,Other,,
1104,652030,1,2,,92709227,5213,Inactive,,,,,Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: Fluorescence-based biochemical gel-based ABPP inhibition and selectivity,Other,,
1105,652030,1,2,1.0,92709227,5213,Inactive,9966764.0,11313.0,,,Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: Fluorescence-based biochemical gel-based ABPP inhibition and selectivity,Other,,
1106,652030,1,2,2.0,92709227,5213,Inactive,123122209.0,,,,Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: Fluorescence-based biochemical gel-based ABPP inhibition and selectivity,Other,,
1107,652030,1,2,3.0,92709227,5213,Inactive,71059731.0,18777.0,,,Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: Fluorescence-based biochemical gel-based ABPP inhibition and selectivity,Other,,
1108,652039,1,1,,855643,5213,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
1109,652048,1,2,,855643,5213,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
1110,652051,1,1,,855643,5213,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
1111,652054,1,1,,855643,5213,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
1112,652067,1,4,,855643,5213,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
1113,652104,1,1,,855643,5213,Inactive,20140568.0,23435.0,,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
1114,652105,1,1,,855643,5213,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
1115,652106,1,1,,855643,5213,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
1116,652115,1,1,,855643,5213,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
1117,652126,1,3,,855643,5213,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
1118,652154,1,1,,855643,5213,Inactive,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1119,652162,2,1,,855643,5213,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1120,652163,1,1,,855643,5213,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1121,652197,1,1,,855643,5213,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1122,652257,1,1,,855643,5213,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
1123,657573,2,3,,131275778,5213,Unspecified,,,284.0,IC50,Antioxidant activity assessed as DPPH radical scavenging activity by densitometric analysis,Confirmatory,22503365.0,
1124,678839,1,8,,131275778,5213,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: cell accumulation of daunomycin in MDA435/LCC6MDR1 cells,Other,12604704.0,
1125,679737,1,8,,131275778,5213,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: increase in Daunomycin intracellular accumulation (Daunomycin: 0.05 uM, Silymarin: 50 uM) in MDA435/LCC6 MDR1 cells",Other,12604704.0,
1126,680678,1,8,,131275778,5213,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: increase in digoxin intracellular accumulation (digoxin: 11nM, silymarin: 100 uM) in Caco-2 cells",Other,12948016.0,
1127,680680,1,8,,131275778,5213,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: increase in digoxin intracellular accumulation (VBL: 27nM, silymarin: 100 uM) in Caco-2 cells",Other,12948016.0,
1128,681179,1,8,,131275778,5213,Unspecified,67462103.0,9429.0,,,"TP_TRANSPORTER: increase in mitoxantrone intracellular accumulation (Mitoxantrone: 20 uM, Silymarin: 50 uM) in BCRP-expressing NCI-H460 cells",Other,15102949.0,
1129,681180,1,8,,131275778,5213,Unspecified,67462103.0,9429.0,,,"TP_TRANSPORTER: increase in mitoxantrone intracellular accumulation (Mitoxantrone: 20 uM, Silybin: 50 uM) in BCRP-expressing NCI-H460 cells",Other,15102949.0,
1130,681194,1,8,,131275778,5213,Unspecified,67462103.0,9429.0,,,"TP_TRANSPORTER: increase in mitoxantrone intracellular accumulation (Mitoxantrone: 100 uM, Silymarin: 50 uM) in BCRP-expressing MCF-7 cells",Other,15102949.0,
1131,681195,1,8,,131275778,5213,Unspecified,67462103.0,9429.0,,,"TP_TRANSPORTER: increase in mitoxantrone intracellular accumulation (Mitoxantrone: 100 uM, Silybin: 50 uM) in BCRP-expressing MCF-7 cells",Other,15102949.0,
1132,681308,1,8,,131275778,5213,Unspecified,296439301.0,4363.0,,,"TP_TRANSPORTER: increase in Vinblastine intracellular accumulation (Vinblastine: 0.05 uM, Silymarin: 100 uM) in Panc-1 cells",Other,12532374.0,
1133,681319,1,8,,131275778,5213,Unspecified,296439301.0,4363.0,,,"TP_TRANSPORTER: increase in Daunomycin intracellular accumulation (Daunomycin: 0.05 uM, Silymarin: 100 uM) in Panc-1 cells",Other,12532374.0,
1134,686940,1,1,,855643,5213,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
1135,686964,1,1,,855643,5213,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
1136,686970,1,2,,855643,5213,Inactive,49168486.0,3417.0,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
1137,686971,1,2,,855643,5213,Inconclusive,,,20.5962,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
1138,686978,1,1,,855643,5213,Active,79154014.0,55775.0,20.5962,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1139,686978,1,1,,124883412,5213,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1140,686979,1,1,,855643,5213,Active,79154014.0,55775.0,12.9953,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1141,686979,1,1,,124883412,5213,Inconclusive,79154014.0,55775.0,29.0929,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1142,686992,2,1,,855643,5213,Inactive,187960042.0,6401.0,,,Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity,Screening,,
1143,687014,1,1,,855643,5213,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
1144,687016,1,1,,855643,5213,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
1145,697852,1,7,,131275778,5213,Unspecified,14916521.0,,,,Inhibition of electric eel AChE at 2 mg/ml by Ellman's method,Other,23062825.0,
1146,697853,1,7,,131275778,5213,Unspecified,21362409.0,100033901.0,,,Inhibition of horse BChE at 2 mg/ml by Ellman's method,Other,23062825.0,
1147,716204,1,7,,131275778,5213,Unspecified,14916521.0,,,,Inhibition of electric eel AChE at 100 uM by colorimetric Ellman assay,Other,22624880.0,
1148,716205,1,7,,131275778,5213,Unspecified,21362409.0,100033901.0,,,Inhibition of horse AChE at 100 uM by colorimetric Ellman assay,Other,22624880.0,
1149,716210,1,3,,131275778,5213,Unspecified,,,,,Neurotoxicity in mouse hippocampal HT22 cells assessed as cell viability at 50 uM after 24 hrs by MTT assay,Other,22624880.0,
1150,716211,1,3,,131275778,5213,Inactive,,,,,Neuroprotective activity against glutamate induced oxidative stress in mouse hippocampal HT22 cells assessed as cell viability at 1 uM after 24 hrs by MTT assay,Other,22624880.0,
1151,716424,1,3,,131275778,5213,Inactive,,,,,Neuroprotective activity against glutamate induced oxidative stress in mouse hippocampal HT22 cells assessed as cell viability at 10 uM after 24 hrs by MTT assay,Other,22624880.0,
1152,716425,1,3,,131275778,5213,Inactive,,,,,Neuroprotective activity against glutamate induced oxidative stress in mouse hippocampal HT22 cells assessed as cell viability at 25 uM after 24 hrs by MTT assay,Other,22624880.0,
1153,716426,1,3,,131275778,5213,Inactive,,,,,Neuroprotective activity against glutamate induced oxidative stress in mouse hippocampal HT22 cells assessed as cell viability at 50 uM after 24 hrs by MTT assay,Other,22624880.0,
1154,716439,1,2,,131275778,5213,Unspecified,,,,,Hepatotoxicity against Wistar rat assessed as increase in tissue content of oxidised glutathione at 2 uM/100 gram of body weight after 24 hrs,Other,22624880.0,
1155,716440,1,2,,131275778,5213,Unspecified,,,,,"Hepatotoxicity against Wistar rat assessed as increase in tissue content of oxidised glutathione at 6 uM/100 gram of body weight, ip after 24 hrs",Other,22624880.0,
1156,716441,1,2,,131275778,5213,Active,,,,,"Hepatoprotective against tacrine-induced toxicity in Wistar rat liver assessed as increase in ratio of reduced/oxidised glutathione at 2 uM/100 gram of body weight, ip after 24 hrs",Other,22624880.0,
1157,716442,1,2,,131275778,5213,Active,,,,,"Hepatoprotective against tacrine-induced toxicity in Wistar rat liver assessed as increase in ratio of reduced/oxidised glutathione at 6 uM/100 gram of body weight, ip after 24 hrs",Other,22624880.0,
1158,716443,1,2,,131275778,5213,Unspecified,,,,,"Hepatoprotective activity against tacrine-induced toxicity in Wistar rat liver assessed as decrease in tissue content of TBARS at 2 uM/100 gram of body weight, ip after 24 hrs",Other,22624880.0,
1159,716445,1,2,,131275778,5213,Active,,,,,Antiamnesic activity against scopolamine-induced cognitive impairment in Wistar rat assessed as reduction in number of error made at 2 umol/100 g body weight after 20 to 120 mins by eight arm radial maze test,Other,22624880.0,
1160,720504,1,1,,855643,5213,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
1161,720508,1,1,,855643,5213,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
1162,720509,1,1,,855643,5213,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
1163,720511,1,1,,855643,5213,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
1164,720532,1,1,,124883412,5213,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1165,720533,1,1,,124883412,5213,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1166,720542,1,2,,855643,5213,Inactive,23496270.0,810891.0,28.1838,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
1167,720543,1,1,,855643,5213,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
1168,720551,1,2,,855643,5213,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
1169,720553,1,2,,855643,5213,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
1170,720579,2,1,,855643,5213,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
1171,720579,2,1,,124883412,5213,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
1172,720580,1,1,,855643,5213,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
1173,720580,1,1,,124883412,5213,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
1174,720582,1,1,,855643,5213,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
1175,720596,1,1,,855643,5213,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
1176,720641,1,2,,92221971,5213,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
1177,720647,1,2,,855643,5213,Inactive,,,,,Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition,Screening,,
1178,720648,1,1,,855643,5213,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
1179,720700,1,4,,855643,5213,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
1180,720702,1,1,,855643,5213,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
1181,720704,1,4,,855643,5213,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
1182,720707,1,2,,855643,5213,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
1183,720708,1,2,,855643,5213,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
1184,720709,1,2,,855643,5213,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
1185,720711,1,2,,855643,5213,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
1186,720717,1,3,,92221971,5213,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
1187,724311,1,2,,131275778,5213,Unspecified,,,,,Inhibition of NF-kappaB (unknown origin) expressed in TNFalpha-stimulated rat HSC-T6 cells assessed as reduction of HSC activation at 10 ug/ml treated 30 mins before TNFalpha stimulation measured after 6 hrs by bioluminescence based luciferase reporter gene assay relative to control,Other,23265871.0,
1188,743126,1,1,,855643,5213,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
1189,743238,1,1,,855643,5213,Inactive,,,,,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,Screening,,
1190,743247,1,2,,855643,5213,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1191,743255,1,1,,855643,5213,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
1192,743266,1,2,,855643,5213,Inactive,296080761.0,5745.0,50.1187,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
1193,743269,1,1,,855643,5213,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
1194,743269,1,1,,855643,5213,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
1195,743279,1,2,,855643,5213,Inactive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
1196,743287,1,1,,855643,5213,Inactive,,,,,Luminescent GLuc Reporter Gene Assay Primary HTS to Identify Small Molecule Activator of Glucose Dependent Insulin Secretion Measured in Cell-Based System Using Plate Reader - 7055-01_Activator_SinglePoint_HTS_Activity,Screening,,
1197,743397,1,1,,855643,5213,Inactive,,,,,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1198,743398,1,1,,855643,5213,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
1199,755104,1,2,,131275778,5213,Active,,,,,Inhibition of UGT in human liver microsomes using 4-methylumbelliferone as substrate after 10 mins by fluorescence analysis,Other,23673225.0,
1200,755105,1,5,,131275778,5213,Unspecified,117157.0,1577.0,,,Inhibition of CYP3A4/5 in human intestinal microsomes using midazolam as substrate after 4 mins,Other,23673225.0,
1201,755105,1,5,,131275778,5213,Unspecified,116241312.0,1576.0,,,Inhibition of CYP3A4/5 in human intestinal microsomes using midazolam as substrate after 4 mins,Other,23673225.0,
1202,755106,1,5,,131275778,5213,Unspecified,6686268.0,1559.0,,,Inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate after 30 mins,Other,23673225.0,
1203,755108,1,3,,131275778,5213,Active,,,,,Antiviral activity against HCV JFH-1 infected in human Huh7.5.1 cells assessed as viral core protein expression at 6.2 to 62.1 uM after 72 hrs by Western blot analysis,Other,23673225.0,
1204,755112,1,2,,131275778,5213,Unspecified,,,80.0,IC50,Cytotoxicity against human Huh7.5.1 cells after 72 hrs,Confirmatory,23673225.0,
1205,767621,1,1,,131275778,5213,Unspecified,,,400.0,IC50,Cytotoxicity against human HT1080 cells,Confirmatory,23953690.0,
1206,768887,1,5,,131275778,5213,Active,135807.0,2147.0,,,Inhibition of human thrombin assessed as inhibition of fibrinogen polymerization at 1000 uM preincubated for 10 mins followed by fibrionogen addition measured for 20 mins,Other,24610996.0,
1207,768888,2,3,,131275778,5213,Active,254763341.0,5328.0,21.0,IC50,Inhibition of urokinase amidolytic activity (unknown origin),Confirmatory,24610996.0,
1208,768889,2,1,,131275778,5213,Active,136408.0,5644.0,3.7,IC50,Inhibition of trypsin amidolytic activity (unknown origin),Confirmatory,24610996.0,
1209,768889,2,1,,131275778,5213,Active,136413.0,5645.0,3.7,IC50,Inhibition of trypsin amidolytic activity (unknown origin),Confirmatory,24610996.0,
1210,768889,2,1,,131275778,5213,Active,209572698.0,5646.0,3.7,IC50,Inhibition of trypsin amidolytic activity (unknown origin),Confirmatory,24610996.0,
1211,768890,2,3,,131275778,5213,Active,135807.0,2147.0,20.9,IC50,Inhibition of thrombin (unknown origin) assessed as hydrolysis of N-benzoyl-phenylalanylvalyl-arginine-paranitroanilide,Confirmatory,24610996.0,
1212,768892,1,5,,131275778,5213,Active,135807.0,2147.0,,,Competitive inhibition of human thrombin using D-Phe-Pip-Arg-pNA as substrate preincubated for 10 mins followed by substrate addition measured every 12 secs for 10 mins by Lineweaver-Burk plot analysis,Other,24610996.0,
1213,768893,3,2,,131275778,5213,Unspecified,135807.0,2147.0,,,Inhibition of human thrombin assessed as equilibrium association constant at 50 to 1000 uM by BIAcore analysis,Other,24610996.0,
1214,768894,4,2,,131275778,5213,Active,135807.0,2147.0,18.6,Kd,Inhibition of human thrombin assessed as equilibrium dissociation constant at 50 to 1000 uM by BIAcore analysis,Confirmatory,24610996.0,
1215,768895,1,5,,131275778,5213,Unspecified,135807.0,2147.0,,,Inhibition of human thrombin assessed as response unit at 1000 uM by BIAcore analysis,Other,24610996.0,
1216,768899,1,5,,131275778,5213,Active,135807.0,2147.0,,,Inhibition of human thrombin assessed as decrease in platelet aggregation at 25 to 250 uM preincubated for 10 mins measured for 10 mins by dual channel chrono-log aggregometric analysis,Other,24610996.0,
1217,768900,1,5,,131275778,5213,Unspecified,135807.0,2147.0,,,Inhibition of human thrombin assessed as decrease in platelet aggregation at 1000 uM preincubated for 10 mins measured for 10 mins by dual channel chrono-log aggregometric analysis relative to control,Other,24610996.0,
1218,768907,1,5,,131275778,5213,Inactive,135807.0,2147.0,,,Inhibition of human thrombin assessed as inhibition of fibrinogen alpha-polymer formation at 250 uM after 15 mins by SDS-PAGE analysis,Other,24610996.0,
1219,768908,1,5,,131275778,5213,Inactive,135807.0,2147.0,,,Inhibition of human thrombin assessed as inhibition of fibrinogen gamma-gamma chain formation at 250 uM after 15 mins by SDS-PAGE analysis,Other,24610996.0,
1220,768909,1,5,,131275778,5213,Active,135807.0,2147.0,,,Inhibition of human thrombin assessed as inhibition of fibrinogen alpha-polymer formation at 250 uM after 5 mins by SDS-PAGE analysis,Other,24610996.0,
1221,768910,1,5,,131275778,5213,Active,135807.0,2147.0,,,Inhibition of human thrombin assessed as inhibition of fibrinogen gamma-gamma chain formation at 250 uM after 5 mins by SDS-PAGE analysis,Other,24610996.0,
1222,768927,1,5,,131275778,5213,Unspecified,135807.0,2147.0,,,Inhibition of human thrombin assessed as inhibition of fibrinogen polymerization preincubated for 10 mins followed by fibrionogen addition measured for 20 mins,Other,24610996.0,
1223,768929,2,3,,131275778,5213,Unspecified,135807.0,2147.0,,IC50,Inhibition of human thrombin amidolytic activity using D-Phe-Pip-Arg-pNA as substrate preincubated for 10 mins followed by substrate addition measured every 12 secs for 10 mins by spectrophotometric analysis,Confirmatory,24610996.0,
1224,779150,1,2,,131275778,5213,Unspecified,,,,,Inhibition of Wnt/beta-catenin signaling pathway in human HEK293 cells at 20 uM after 24 hrs by dual luciferase reporter gene assay relative to vehicle-treated control,Other,24018191.0,
1225,977599,1,1,,131275778,5213,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
1226,977600,1,1,,131275778,5213,Active,,,6.16595,IC50,pIC50 values for sodium fluorescein (10 uM) uptake in OATP1B1-transfected CHO cells,Confirmatory,23571415.0,
1227,977601,1,1,,131275778,5213,Active,,,3.37,Ki,Ki values for sodium fluorescein (10 uM) uptake in OATP1B1-transfected CHO cells,Confirmatory,23571415.0,
1228,977602,1,2,,131275778,5213,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
1229,977603,1,2,,131275778,5213,Active,,,4.2658,IC50,pIC50 values for sodium fluorescein (10 uM) uptake in OATP1B3-transfected CHO cells,Confirmatory,23571415.0,
1230,977604,1,2,,131275778,5213,Active,,,3.27,Ki,Ki values for sodium fluorescein (10 uM) uptake in OATP1B3-transfected CHO cells,Confirmatory,23571415.0,
1231,1053175,2,1,,178126607,5213,Inactive,,,,,A screen for compounds that inhibit growth of Escherichia coli,Other,,
1232,1053175,2,1,,178127219,5213,Inactive,,,,,A screen for compounds that inhibit growth of Escherichia coli,Other,,
1233,1053197,1,1,,855643,5213,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
1234,1122046,1,1,,131275778,5213,Active,,,,,"Hepatoprotective activity against thioacetamide-induced liver toxicity in Swiss albino mouse assessed as protection against histological damage at 20 mg/kg, po administered for 7 days started 1 day after thioacetamide challenge measured on day 8 by hematoxylin-eosin staining",Other,,
1235,1122047,1,1,,131275778,5213,Unspecified,,,,,"Hepatoprotective activity against thioacetamide-induced liver toxicity in Swiss albino mouse assessed as protection in serum total bilirubin activity at 20 mg/kg, po administered for 7 days started 1 day after thioacetamide challenge measured on day 8",Other,,
1236,1122048,1,1,,131275778,5213,Unspecified,,,,,"Hepatoprotective activity against thioacetamide-induced liver toxicity in Swiss albino mouse assessed as protection in serum ALP activity at 20 mg/kg, po administered for 7 days started 1 day after thioacetamide challenge measured on day 8",Other,,
1237,1122049,1,1,,131275778,5213,Unspecified,,,,,"Hepatoprotective activity against thioacetamide-induced liver toxicity in Swiss albino mouse assessed as protection in serum AST activity at 20 mg/kg, po administered for 7 days started 1 day after thioacetamide challenge measured on day 8",Other,,
1238,1122050,1,1,,131275778,5213,Unspecified,,,,,"Hepatoprotective activity against thioacetamide-induced liver toxicity in Swiss albino mouse assessed as protection in serum ALT activity at 20 mg/kg, po administered for 7 days started 1 day after thioacetamide challenge measured on day 8",Other,,
1239,1129260,1,3,,131275778,5213,Inactive,13432234.0,5468.0,,,Agonist activity at human PPAR-gamma expressed in HEK293 cells at 30 ug/ml after 18 hrs by luciferase reporter gene assay relative to control,Other,24597776.0,
1240,1159524,1,1,,855643,5213,Inconclusive,,,17.7828,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
1241,1159524,1,1,,124883412,5213,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
1242,1159583,2,1,,178126607,5213,Inactive,,,,,High throughput screen for small molecule inhibitors of a hypoxia-regulated fluorescent biosensor in Mycobacterium tuberculosis,Other,,
1243,1159583,2,1,,178127219,5213,Inactive,,,,,High throughput screen for small molecule inhibitors of a hypoxia-regulated fluorescent biosensor in Mycobacterium tuberculosis,Other,,
1244,1159606,1,1,,855643,5213,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
1245,1159620,1,1,,131275778,5213,Active,,,,,Summary of drug indications.,Other,,
1246,1172632,1,2,,131275778,5213,Unspecified,,,392.2,IC50,Antioxidant activity assessed as DPPH radical scavenging activity after 10 mins,Confirmatory,25442301.0,
1247,1172633,1,1,,131275778,5213,Unspecified,,,,,Toxicity in human MKN28 cells assessed as cell viability at 10 to 200 uM after 48 hrs by MTT assay,Other,25442301.0,
1248,1172634,1,2,,131275778,5213,Unspecified,2506326.0,7498.0,,,Inhibition of xanthine oxidase in human MKN28 cells assessed as inhibition of xanthine oxidase-induced cell damage by measuring cell viability at 10 to 200 uM after 48 hrs by MTT assay,Other,25442301.0,
1249,1214756,1,1,,131275778,5213,Unspecified,,,,,Cmax in patient with chronic noncirrhotic HCV infection at 700 mg,Other,23401473.0,
1250,1214757,1,1,,131275778,5213,Unspecified,,,,,Cmax in patient with chronic noncirrhotic HCV infection at 140 mg,Other,23401473.0,
1251,1214758,1,2,,131275778,5213,Active,12643959.0,10599.0,,,Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells assessed as reduction of [3H]estradiol-17beta-glucuronide uptake at 10 uM after 3 mins by beta-counting,Other,23401473.0,
1252,1214759,1,2,,131275778,5213,Active,27734563.0,28234.0,,,Inhibition of OATP1B3 (unknown origin) expressed in HEK293 cells assessed as reduction of [3H]estradiol-17beta-glucuronide uptake at 10 uM after 3 mins by beta-counting,Other,23401473.0,
1253,1214760,1,2,,131275778,5213,Active,313104012.0,11309.0,,,Inhibition of OATP2B1 (unknown origin) expressed in MDCK2 cells assessed as reduction of [3H]estrone-3-sulfate uptake at 10 uM after 3 mins by beta-counting,Other,23401473.0,
1254,1214761,1,2,,131275778,5213,Active,12643959.0,10599.0,9.7,IC50,Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells assessed as reduction of [3H]estradiol-17beta-glucuronide uptake after 3 mins by beta-counting,Confirmatory,23401473.0,
1255,1214762,1,2,,131275778,5213,Active,27734563.0,28234.0,2.7,IC50,Inhibition of OATP1B3 (unknown origin) expressed in HEK293 cells assessed as reduction of [3H]estradiol-17beta-glucuronide uptake after 3 mins by beta-counting,Confirmatory,23401473.0,
1256,1214763,1,2,,131275778,5213,Active,313104012.0,11309.0,4.5,IC50,Inhibition of OATP2B1 (unknown origin) expressed in MDCK2 cells assessed as reduction of [3H]estrone-3-sulfate uptake after 3 mins by beta-counting,Confirmatory,23401473.0,
1257,1214764,1,1,,131275778,5213,Unspecified,,,,,Fraction absorbed in rat,Other,23401473.0,
1258,1214765,1,2,,131275778,5213,Inactive,12643959.0,10599.0,,,Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells assessed as reduction of [3H]estradiol-17beta-glucuronide uptake after 3 mins by beta-counting in presence of OATP inhibitor BSP,Other,23401473.0,
1259,1214766,1,2,,131275778,5213,Inactive,27734563.0,28234.0,,,Inhibition of OATP1B3 (unknown origin) expressed in HEK293 cells assessed as reduction of [3H]estradiol-17beta-glucuronide uptake after 3 mins by beta-counting in presence of OATP inhibitor BSP,Other,23401473.0,
1260,1214767,1,2,,131275778,5213,Inactive,313104012.0,11309.0,,,Inhibition of OATP2B1 (unknown origin) expressed in MDCK2 cells assessed as reduction of [3H]estrone-3-sulfate uptake after 3 mins by beta-counting in presence of OATP inhibitor BSP,Other,23401473.0,
1261,1214768,1,1,,131275778,5213,Active,,,,,Inhibition of OATP-mediated [3H]estradiol-17beta-glucuronide uptake in sandwich-cultured human hepatocytes at 100 uM after 1 day by beta-counting,Other,23401473.0,
1262,1214769,1,1,,131275778,5213,Active,,,,,Inhibition of OATP-mediated [3H]rosuvastatin uptake in sandwich-cultured human hepatocytes at 100 uM after 1 day by beta-counting,Other,23401473.0,
1263,1214770,1,1,,131275778,5213,Unspecified,,,,,Inhibition of OATP-mediated [3H]estradiol-17beta-glucuronide uptake in sandwich-cultured human hepatocytes at 100 uM after 8 days by beta-counting,Other,23401473.0,
1264,1214771,1,1,,131275778,5213,Active,,,,,Inhibition of OATP-mediated [3H]rosuvastatin uptake in sandwich-cultured human hepatocytes at 100 uM after 8 days by beta-counting,Other,23401473.0,
1265,1214772,1,1,,131275778,5213,Active,,,,,Plasma concentration in patient with chronic noncirrhotic HCV at 420 to 700 mg administered 3 times per day,Other,23401473.0,
1266,1214773,1,1,,131275778,5213,Unspecified,,,,,Protein binding in rat,Other,23401473.0,
1267,1214774,1,2,,131275778,5213,Unspecified,,,,,Unbound fraction in human plasma,Other,23401473.0,
1268,1214775,1,1,,131275778,5213,Active,,,,,Cmax at steady state in patient with chronic HCV infection at 140 mg administered 3 times per day,Other,23401473.0,
1269,1214776,1,1,,131275778,5213,Active,,,,,fCmax in portal vein of patient with chronic noncirrhotic HCV infection at 140 mg,Other,23401473.0,
1270,1214777,1,1,,131275778,5213,Active,,,,,fCmax in portal vein of patient with chronic noncirrhotic HCV infection at 700 mg,Other,23401473.0,
1271,1214778,1,1,,131275778,5213,Unspecified,,,,,Ratio of fCmax in portal vein of patient with chronic noncirrhotic HCV infection at 700 mg to IC50 for OATP1B1 (unknown origin) expressed in HEK293 cells,Other,23401473.0,
1272,1214779,1,1,,131275778,5213,Unspecified,,,,,Ratio of fCmax in portal vein of patient with chronic noncirrhotic HCV infection at 140 mg to IC50 for OATP1B1 (unknown origin) expressed in HEK293 cells,Other,23401473.0,
1273,1214780,1,1,,131275778,5213,Unspecified,,,,,Ratio of fCmax in portal vein of patient with chronic noncirrhotic HCV infection at 700 mg to IC50 for OATP1B3 (unknown origin) expressed in HEK293 cells,Other,23401473.0,
1274,1214781,1,1,,131275778,5213,Unspecified,,,,,Ratio of fCmax in portal vein of patient with chronic noncirrhotic HCV infection at 140 mg to IC50 for OATP1B3 (unknown origin) expressed in HEK293 cells,Other,23401473.0,
1275,1214782,1,1,,131275778,5213,Unspecified,,,,,Ratio of fCmax in portal vein of patient with chronic noncirrhotic HCV infection at 700 mg to IC50 for OATP2B1 (unknown origin) expressed in HEK293 cells,Other,23401473.0,
1276,1214783,1,1,,131275778,5213,Unspecified,,,,,Ratio of fCmax in portal vein of patient with chronic noncirrhotic HCV infection at 140 mg to IC50 for OATP2B1 (unknown origin) expressed in HEK293 cells,Other,23401473.0,
1277,1224865,1,2,,855643,5213,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
1278,1224905,2,1,,92221971,5213,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
1279,1224905,2,1,,92221971,5213,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
1280,1239596,1,1,,131275778,5213,Unspecified,,,,,Inhibition of biofilm formation in Staphylococcus aureus 8325-4 after 24 hrs by microtiter plate assay,Other,26273725.0,
1281,1239597,1,1,,131275778,5213,Unspecified,,,,,Toxicity in Staphylococcus aureus 8325-4 assessed as inhibition of bacterial growth,Other,26273725.0,
1282,1239598,1,1,,131275778,5213,Inactive,,,,,Disruption of biofilm formation in Staphylococcus aureus 8325-4 after 24 hrs by microtiter plate assay,Other,26273725.0,
1283,1254733,1,1,,131275778,5213,Unspecified,,,,,Oral bioavailability in human,Other,26125082.0,
1284,1254734,1,1,,131275778,5213,Unspecified,,,,,Terminal half life in orally dosed human by LC-MS/MS method,Other,26125082.0,
1285,1259309,1,1,,178126607,5213,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220 with the processive glycosyltransferase UgtP deleted,Other,,
1286,1259309,1,1,,178127219,5213,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220 with the processive glycosyltransferase UgtP deleted,Other,,
1287,1259310,1,1,,321942529,5213,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
1288,1259310,1,1,,332876287,5213,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
1289,1259310,1,1,,332876397,5213,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
1290,1259310,1,1,,332876495,5213,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
1291,1259311,1,1,,178126607,5213,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220,Other,,
1292,1259311,1,1,,178127219,5213,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220,Other,,
1293,1259313,1,1,,855643,5213,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
1294,1259318,1,1,,855643,5213,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
1295,1259415,1,1,,855643,5213,Active,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
